Stockmann Group's Half year financial report 1 January - 30 June 2017

STOCKMANN plc, Half year financial report 16.8.2017 at 8:00 EET April-June 2017, continuing operations:- Consolidated revenue was EUR 281.3 million (320.7).- Revenue in comparable businesses was down by 4.0%.- Gross margin was 56.1% (57.3).- Operating result was EUR 14.6 million (17.5). January-June 2017, continuing operations:- Consolidated revenue was EUR 498.1 million (563.9).- Revenue in comparable businesses was down by 2.9%.- Gross margin was 54.9% (55.4).- Operating result was EUR -10.5 million (-8.9). - Earnings per share were EUR -0.42 (-0.36). - In June, Stockmann signed an agreement on the sale of the Stockmann Delicatessen operations in Finland to S Group’s regional cooperatives. If approval is granted by the Finnish Competition and Consumer Authority during 2017, the transaction can be completed at the end of 2017.- The food operations in Finland have been classified as an asset held for sale and reported as discontinued operations. The comparison figures in the Group and Stockmann Retail income statement and related items have been restated accordingly. The comments in the half year financial report refer only to continuing operations.- Stockmann Delicatessen in the Baltic countries will remain with Stockmann and is reported as a part of Stockmann Retail’s continuing operations. Guidance for 2017 remains unchanged:Stockmann expects the Group’s revenue for 2017 to decline due to changes in the store network and product mix. Adjusted operating profit is expected to improve, compared with 2016. CEO LAURI VEIJALAINEN: Stockmann’s strategic journey progressed in the second quarter. As the most visible step, we announced the sale of Stockmann Delicatessen in Finland to S Group. In the quarter, I am particularly satisfied that both Stockmann Retail and Real Estate clearly improved their operating profit, by over EUR 10 million in total. However, due to the weakened profitability of Lindex in Sweden, the Group’s operating result in the quarter was down on the previous year. Stockmann Retail delivered a good second quarter. Comparable revenue has now stabilised and we achieved slight sales growth in fashion and cosmetics. The decisions and actions taken are starting to be visible. As a result, Retail’s operating result improved significantly. A lot remains to be done, but our direction is definitely the correct one. Real Estate continued its stable performance, supported by the strengthened Russian rouble which boosted rental income from the Nevsky shopping centre. An investigation into the possible divestment of the property is ongoing according to plan. For Lindex, revenue and subsequently the result was adversely impacted by the weakening market in Sweden and intensive campaigning. Outside the Nordic countries, Lindex continued to grow its revenue but this was not enough to retain the highest ever operating profit, which Lindex achieved a year ago. Action will be taken to improve sales and profitability. We will also continue to invest in digitalisation and strong campaigns, to succeed during the important autumn season. We continue to focus on our key businesses and improving profitability in all three divisions. I am confident that we now have the capabilities to drive growth again in our Stockmann Retail business and to make this division profitable in 2018. KEY FIGURES Continuing operations 4-6/ Restated Restated Restated Restated 2017 4-6/ 1-6/ 1-6/ 1-12/ 2016 2017 2016 2016Revenue, EUR mill. 281.3 320.7 498.1 563.9 1 175.7Gross margin, % 56.1 57.3 54.9 55.4 55.8EBITDA, EUR mill. 29.5 32.0 19.4 19.1 85.6Adjusted EBITDA*, EUR mill. 29.5 32.0 19.4 19.1 88.2Operating result (EBIT), EUR 14.6 17.5 -10.5 -8.9 28.3mill.Adjusted operating result 14.6 17.5 -10.5 -8.9 30.9(EBIT)*, EUR mill.Net financial items**, EUR mill. -10.8 -4.7 -15.4 -8.9 -23.1Result before tax, EUR mill. 3.8 12.8 -25.9 -17.8 5.2Result for the period, EUR mill. -1.1 4.6 -28.0 -23.0 -7.5Earnings per share, -0.03 0.05 -0.42 -0.36 -0.18undiluted and diluted, EURPersonnel, average 7 224 8 273 7 217 8 343 8 151 Continuing and discontinued 4-6/ 4-6/ 1-6/ 1-6/ 1-12/operations*** 2017 2016 2017 2016 2016Net earnings per share, -0.09 -0.04 -0.52 -0.35 -0.12undiluted and diluted, EURCash flow from operating 48.2 54.4 -29.9 -20.9 41.5activities, EUR mill.Capital expenditure, EUR mill. 7.9 13.6 15.7 19.5 44.2Equity per share, EUR 14.32 14.19 14.99Net gearing, % 76.5 76.2 68.3Equity ratio, % 46.9 46.0 48.3Number of shares, undiluted and 72 049 72 049 72 049diluted, weighted average, 1 000pcReturn on capital employed, 1.3 -4.6 1.8rolling 12 months, % * There were no adjustments made in the second quarter, neither in 2017 nor in 2016. For full-year 2016, adjustments affecting operating result were EUR 2.6 million and they were mostly related to ICT outsourcing.** Includes a write-off of EUR 3.8 million related to Stockmann’s investment in Tuko Logistics Cooperative.*** Discontinued operations include department store operations in Russia which were sold in the first quarter of 2016, and Stockmann Delicatessen food operations in Finland which are expected to be divested at the end of 2017. Stockmann uses Alternative Performance Measures according to the guidelines of the European Securities and Market Authority (ESMA) to better reflect the operational business performance and to facilitate comparisons between financial periods. Gross profit is calculated by deducting the costs of goods sold from the revenue, and gross margin is calculated by dividing gross profit by the revenue as a percentage. EBITDA is calculated from operating result excluding depreciation. Adjusted EBITDA and adjusted operating result (EBIT) are measures which exclude non-recurring items affecting comparability from the reported EBITDA and reported operating result (EBIT). Stockmann also uses the term “revenue in comparable businesses” which refers to revenue excluding Hobby Hall, which was divested on 31 December 2016, the Oulu department store, which was closed on 31 January 2017, and the Lindex stores in Russia, which were closed in 2016. OUTLOOK FOR 2017 In the Stockmann Group’s largest operating country, Finland, the economy has begun to recover. GDP and the retail market are expected to grow in 2017. Consumers’ purchasing power is, however, not expected to increase and purchasing behaviour is changing due to digitalisation and increasing competition. The Swedish economy remained stable in 2016 and the GDP growth estimate for 2017 remains on a higher level than in Finland. The steady growth in the fashion market stagnated in 2016, and the market is expected to decline in 2017. In the Baltic countries, GDP growth is estimated to continue. The outlook for these countries is expected to be better than that for the Stockmann Group’s other market areas. The Russian economy is expected to recover gradually, but the purchasing power of Russian consumers remains low. Stockmann will continue improving the Group’s long-term competitiveness and profitability. The efficiency measures launched in summer 2016 will be fully visible in the 2017 operating costs. Improvements in the operating result in 2017 are estimated to come mainly from the Stockmann Retail division, which is still loss-making, while Real Estate is expected to continue its stable profitable performance. Lindex’s operating profit in 2017 will be clearly down on the previous year’s record-high earnings. The planned sale of the Delicatessen business in Finland is expected to improve the Group’s profitability from 2018 onwards. Capital expenditure for 2017 is estimated to be approximately EUR 45-50 million, which is less than the estimated depreciation for the year. GUIDANCE FOR 2017 Stockmann expects the Group’s revenue for 2017 to decline due to changes in the store network and product mix. Adjusted operating profit is expected to improve, compared with 2016. Half year financial report 2017This company announcement is a summary of the Stockmann's Half year financial report 2017 and includes the most relevant information of the report. The complete report is attached to this release as a pdf file and is also available on the company's website at stockmanngroup.com . Press and analyst briefingA press and analyst briefing will be held today, on 16 August 2017 at 9:15 a.m. EET in the Fazer À la Carte restaurant on the 8th floor of Stockmann’s Helsinki city centre department store, Aleksanterinkatu 52 B. WebcastCEO Lauri Veijalainen will host a webcast in English today, on 16 August 2017, at 11:15 a.m. EET presenting the Half year financial report. To participate in the webcast, please dial one of the numbers below 5–10 minutes before the webcast begins. The presentation can be followed by this link  or on the address stockmanngroup.com.  The recording and presentation material are available on the company's website after the event. Finland: +358 (0)9 7479 0404Sweden: +46 (0)8 5065 3942United Kingdom: +44 (0)330 336 9411United States of America: +1 719 457 1063 Confirmation code: 8630953 Further information:Lauri Veijalainen, CEO, tel. +358 9 121 5062Nora Malin, Director, Corporate Communications, tel. +358 9 121 3558 www.stockmanngroup.com STOCKMANN plc Lauri VeijalainenCEO Distribution:Nasdaq HelsinkiPrincipal media

ICA Gruppen Q2 report 2017

Second quarter of 2017 in summary · Consolidated net sales amounted to SEK 27,198 million (26,222), an increase of 3.7% · Operating profit excluding non-recurring items totalled SEK 1,094 million (1,154) · The sale of ICA Real Estate in Norway and inkClub, and costs ahead of the integration of the acquisition of IKI in Lithuania, affected operating profit excluding nonrecurring items by a combined total of SEK -53 million · Profit for the period was SEK 1,021 million (829). Profit includes capital gains on sales of non-current assets and impairment losses totalling SEK 165 million net (-37) · Earnings per share were SEK 5.06 (4.12) · Cash flow from operating activities amounted to SEK 2,001 million (1,785). Excluding ICA Bank, cash flow was SEK 1,836 million (1,463) · The sale of 12 properties to Secore Fastigheter was completed on 2 June, generating a capital gain of approximately SEK 150 million After the end of the quarter · No significant events have taken place after the end of the quarter Comment from the CEO of ICA Gruppen, Per Strömberg: “We had stable underlying earnings during the second quarter, with Apotek Hjärtat – above all – posting a good quarter. Other businesses have been affected by divestments to varying degrees – particularly the sale of properties in Norway – as well as by ongoing activities and ventures. Higher costs have resulted in a slightly lower operating margin than a year ago, but with a high level of activity it is at the same time natural that there will be variations from quarter to quarter that affect earnings. In the long-term perspective we are on track to meeting our targets.” For further information, please contact: Frans Benson, Head of Investor Relations tel. +46 8-561 500 20 ICA Gruppen press service Tel +46 10 422 52 52 Press and analyst meeting ICA Gruppen is arranging a press and analyst meeting on Wednesday 16 August at 10.00 CET at Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm. CEO Per Strömberg and CFO Sven Lindskog will present the interim report. The conference can also be followed at www.icagruppen.se/investerare. To call in, please dial:    SE +46 8 5050 3050                    UK +44 203 655 1001                Conference PIN: 1839741# Calendar 10 November 2017                Interim report third quarter 14 December 2017                Capital Markets Day 8 February 2018                    Year-end report 2017 This information is such that ICA Gruppen AB is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at time 07.00 CET on Wednesday, August 16, 2017.

Asetek – Q2 2017: Revenue Growth Driven by Gaming PC Cooling Demand

Asetek reported revenue of $11.1 million in the second quarter of 2017, an increase of 33% from the second quarter of 2016 on higher desktop revenue driven by shipments in the DIY and Gaming Performance/ Desktop PC markets. Growth in the quarter also reflects an increase in shipment of data center products to OEMs. Revenue for the six months ending 30 June was $22.6 million, an increase of 21% from the same period of 2016.  “Q2 was another good quarter for Asetek. The demand for our efficient liquid cooling solutions for data centers, servers and PCs continues to grow. For 2017, we expect a decent growth within our desktop segment, especially due to high-end gaming customers. And we expect significant growth within our data center segment on the back of continued progress with OEM partners and increasing end-user adoption with technology deployed to new high performance (HPC) installations. Our job now is to make sure the positive development continues,” said André Sloth Eriksen, CEO and Founder.  EBITDA adjusted for share based compensation expense was was $1.1 million in the second quarter of 2017, compared with EBITDA adjusted of $0.3 million in the second quarter of 2016. First-half 2017 EBITDA adjusted was $1.8 million, compared to $1.6 million for the first half of 2016. Desktop revenue was $10.1 million in the second quarter, an increase of 34% from the same period of 2016. Operating profit from the desktop segment was $2.8 million, an increase from $2.2 million in the same period last year due to an increase in DIY and Gaming Performance/Desktop PC sales. Data center revenue was $1.0 million, an increase from $0.8 million in the prior year due to an increase in shipments to OEM customers, partly offset by a decline in shipments under government contracts. Revenue variability is expected to continue while the Company secures new OEM partners and growth of end-user adoption through existing OEM partners. Asetek continued to invest in its data center business and the segment operating loss was $1.6 million for the second quarter, compared with $1.3 million in the same period of 2016. Expenditures relate to technology development, manufacturing, and sales development with data center partners and OEM customers. Through new and repeat orders received from data center OEM partners in the first half of 2017, Asetek is increasing its end-user adoption with technology deployed to new HPC installations.  In the second quarter, this included orders of RackCDU D2C™ (Direct-to-Chip) liquid cooling from Fujitsu and Penguin Computing. Due to continued positive development within the desktop segment, Asetek increases its full year 2017 desktop revenue guidance from single digit growth to growth between 10% and 20% compared with 2016.  The outlook for the data center business is reaffirmed, with significant revenue growth expected compared with 2016. Webcast and conference call at 8:30 AM CEST today 16 August 2017  Asetek will release its financial results for the second quarter 2017 on Wednesday, 16 August at 7:00 AM CEST. This is followed by a presentation by CEO André Sloth Eriksen and CFO Peter Dam Madsen at 8:30 AM CEST. Asetek invites investors, analysts and media to join the presentation. The presentation is expected to last one hour, including Q&A, and can be followed through live webcast or by conference call. Conference call – audio only:  Please dial in 5-10 minutes prior using the phone numbers and confirmation code below: +-----------------------------------------+------------------------------+|Copenhagen, Denmark:                     |+4532 71 16 59                |+-----------------------------------------+------------------------------+|Oslo, Norway: |+472350 0486 |+-----------------------------------------+------------------------------+|Stockholm, Sweden: |+46(0)8 5033 6538 |+-----------------------------------------+------------------------------+|Frankfurt, Germany: |+49(0)69 2222 10629 |+-----------------------------------------+------------------------------+|London, United Kingdom: |+44(0)20 3427 1916 |+-----------------------------------------+------------------------------+|Paris, France: |+33(0)1 76 77 22 29 |+-----------------------------------------+------------------------------+|New York, United States of America: |+1646 254 3362 |+-----------------------------------------+------------------------------+|Confirmation code: 5557928 |+-----------------------------------------+------------------------------+ Webcast – audio and slide presentation: Please join the second quarter 2017 results webcast by clicking here . The Second Quarter 2017 Report and presentation will also be made available on www.asetek.com and www.newsweb.no, as well as through news agencies. A recorded version of the presentation will be made available on www.asetek.com approximately two hours after the broadcast has concluded. Asetek’s press room is available on www.asetek.com/press-room/news/  For questions or further information, please contact:  CEO and Founder André S. Eriksen, +45 2125 7076, email: ceo@astek.comCFO Peter Dam Madsen, +45 2080 7200, email: investor.relations@asetek.com About Asetek:Asetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK.OL). 

ICA Gruppen’s Sustainability Report for second quarter 2017

“By virtue of our size we have a great responsibility, but on top of this we also clearly see that sustainability is a driver of growth. We see it in our figures, and it is also evident in numerous, independent studies. Companies with effective sustainability work are on average more profitable and deliver higher returns to their shareholders,” says Per Strömberg, CEO ICA Gruppen in his comments on the report. See the Sustainability Report for more information, including: · ICA Gruppen’s greenhouse gas emissions decreased by 41% during the period July 2016–June 2017 compared with the base year 2006. · Continued growth in sales of ecolabelled, organic and ethically labelled products in ICA Sweden’s central assortment. In total, sales of such products during the period July 2016–June 2017 grew 8% compared with the corresponding period a year ago. · New packaging contributing to lower food waste. By changing over to a new form of packaging for large parts of the meat range, considerably longer shelf life has been achieved as well as improved flavour. · Food waste becomes fish in circular system. Waste from potatoes is being used to breed insects, which in turn are being used as fish feed for Arctic char sold under ICA Sweden’s private label. · During the spring Apotek Hjärtat changed over to using plastic bags made of sugar cane. When incinerated the bags produce 85% less CO2than petroleum-based bags. For more informationICA Gruppen press service, Telephone number: +46 10 422 52 52

Ferronordic Machines AB investor presentation 24 August 2017

Ferronordic Machines interim report January - June 2017 will be published on 23 August 2017. An investor presentation will be held by phone on 24 August at 09:00 a.m. CET. Ferronordic Machines will be represented by CEO Lars Corneliusson and CFO Anders Blomqvist.The presentation can be accessed on the company’s website prior to the meeting. To join the presentation, please dial the phone number below no later than five minutes prior to the announced time. Call-in numbers: · Sweden Toll Number: 08 5059 6306 · Sweden Toll-Free Number: 0200 899 908 · UK Toll Number: 0203 139 4830 · UK Toll-Free Number: 0808 237 0030 · Russia Toll Number: 049 564 693 04 · Russia Toll-Free Number: 810 800 2136 5011 Participant code: 65946866# ----------------------------------------- About Ferronordic Machines  Ferronordic is the authorized dealer of Volvo Construction Equipment and Terex Trucks in Russia. It is also the official distributor of Dressta and Rottne in Russia. Ferronordic has also been appointed aftermarket dealer for Volvo and Renault Trucks in certain parts of Russia. The company began its operations in 2010 and has expanded rapidly across Russia. The company is well established in all federal districts with approximately 75 outlets and more than 800 employees. The vision of Ferronordic is to be regarded as the leading service- and sales company in the CIS markets. The preference shares of Ferronordic Machines AB are listed on Nasdaq First North Premier. The company has appointed Avanza Bank AB as its Certified Advisor.www.ferronordic.com  For more information, please contact: Anders Blomqvist, CFO and Head of IR, Tel: +46 8 5090 7280 or anders.blomqvist@ferronordic.com

MenaQ7® Vitamin K2 Again Shown to Inhibit Hardening of Arteries: New Study

OSLO, NORWAY and METUCHEN, NJ (August 16th, 2017) – A new study1 of renal transplant recipients, a group shown to express subclinical vitamin K deficiency, examined whether K2 supplementation would correct this deficiency and thus improve arterial stiffness. The study has published in Journal of the American Society of Hypertension, and the vitamin K2 used in the study was MenaQ7® Vitamin K2 as MK-7 from NattoPharma. This Lebanese study evaluated in the KING trial (a single-arm pilot study) to see if there is an association between vitamin K2 supplementation and the change in both subclinical vitamin K status and indices of arterial stiffness among 60 renal transplant recipients with stable graft function. The results showed that 8 weeks of MK-7 supplementation (360 mcg/day as MenaQ7®) was associated with significant improvement in arterial stiffness and 24-hour peripheral and central pressures. The mean reduction in cfPWV was 1.4 m/s, which was well beyond the reduction of 1 m/s recommended for a clinically relevant vascular effect. “While our previous cardiovascular study in healthy postmenopausal women showed an improvement in arterial elasticity after 3 years of supplementation, the results collected in this trial are staggering, especially as the statistically significant effect was seen very quickly,” says Hogne Vik, chief medical officer of NattoPharma. “After just 8 weeks of MK-7 supplementation, low vitamin K status represented by dpucMGP level was significantly reduced by 55.1%. Moreover, supplementation was associated with a 14.2% reduction in mean cfPWV. “One can assume that longer MK-7 supplementation may lead to even better results, and secure improvement in cardiovascular outcomes in renal transplant patients.”  According to the researchers, prior observational studies have shown the prevalence of subclinical vitamin K deficiency has been reported to be as high as 80% in the renal transplant population. Moreover, in kidney transplant recipients, Vitamin K insufficiency, expressed as a high circulating level of dp-ucMGP (dephosphorylated-uncarboxylated matrix Gla protein, or “inactive” MGP, a K-dependent protein), is associated independently with increased risk of mortality. However, any studies to date have not addressed whether vitamin K supplementation may lead to improved outcomes after kidney transplantation.  In addition, MK-7 supplementation improved vitamin K status, which was represented by the reduction in dp-ucMGP concentrations. A positive correlation was present between the reduction in arterial stiffness, a surrogate of early cardiovascular disease, and the circulating concentration of dp-ucMGP, a marker of subclinical vascular vitamin K deficiency and calcification. The main conclusion was that, among renal transplant recipients with stable graft function, vitamin K2 supplementation was associated with improvement in subclinical K deficiency and arterial stiffness. According to the researchers, the findings from this trial support the hypothesis that subclinical vitamin K deficiency may be a modifiable cardiovascular risk factor and may improve with MK-7 supplementation. “NattoPharma was excited to participate in this clinical trial,” adds Dr. Vik. “We have dedicated ourselves to cultivating an understanding of the benefits Vitamin K2 offers to human health, and in that work have recognized that vitamin K2 deficiency can have serious implications on arterial health. This study adds to the body of evidence confirming the cardiovascular support MenaQ7® Vitamin K2 as MK-7 provides, and continues to solidify the hope this important nutrient offers the global population.” Reference: 1 Mansour AG et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients – a single-arm, single-center clinical trial. J Am Soc Hypertens. 2017 Jul 13. Pii: S1933-1711(17)30255-3. # # # About NattoPharma and MenaQ7® NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com. For more information, please contact: Kate Quackenbush, NattoPharma Director of Communications Phone: 609-643-0749 x 220 E-mail: kate.quackenbush@nattopharma.com

Invitation to presentation of AcadeMedia's full year result for July - June 2016/17

AcadeMedia's full year result for July - June 2016/17 will be published at 08:00 CET on August 30. A web-cast telephone conference will be held at 09:30 CET the same day, where CEO Marcus Strömberg and CFO Eola Änggård Runsten will present the report. The presentation will be held in English and can be followed on the web or over the phone. It will be followed by a Q&A session. To participate in the conference call, and thereby be able to ask questions, call one of the following numbers ten minutes before the start of the call: SE: +46 8 5664 2690UK: +44 20 3008 9801US: +1 855 7532 235 You can follow the presentation and the conference on the following page: https://tv.streamfabriken.com/academedia-q4-2017   The presentation material will be available before the conference begins on AcadeMedia web via https://corporate.academedia.se/finansiell-information/finansiella-rapporter/. It will also be possible to access the recorded version of the webcast after it is finished on this page. About AcadeMedia AcadeMedia creates opportunities for people to develop. The 12,500 employees at our 550 preschools, compulsory schools, upper secondary schools and adult education centres share a common focus on quality and development. Our 140,000 children and students are provided with a high quality education, giving them the best conditions to attain both learning objectives and their full potential as individuals. AcadeMedia is Northern Europe´s largest education company, with locations/facilities/presence in Sweden, Norway and Germany. Our size gives us the capacity to be a robust, long term partner to the communities we serve. More information about AcadeMedia is available on www.academedia.se

Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

Isofol Medical AB (publ), a clinical stage oncology company, announces that a cooperation has been established with Professor Sten Nilsson and Doctor Alain Herrera who have joined Isofol as advisors to its Board of Directors. In addition to several of the World’s leading oncologists being part of Isofol’s Advisory Board this strengthens the company with additional expertise within pharmaceutical business strategy, clinical development, and management of the registration process in preparations for the upcoming pivotal study ISO-CC-007, where Modufolin®, with the support of both FDA in the USA and EMA in Europe, is evaluated as a first-line treatment for metastatic colorectal cancer in an effort to provide data for directly taking Modufolin® to potential drug marketing approval. Professor Sten Nilsson Dr. Nilsson, MD, PhD, is one of Scandinavia's leading clinicians in urological oncology. He has served as a Professor of Oncology at the Karolinska Hospital, Stockholm, Sweden and has wide ranging clinical and research experience in the fields of oncology and nuclear medicine. In the industry, Prof. Nilsson has been part of the advisory boards of several leading pharmaceutical companies such as Bayer Healthcare, Janssen, Ipsen, Novartis, AstraZeneca, Pharmacia/Pfizer, Roche and Lilly. He is founder of Dextech Medical (Aktietorget, Stockholm) and is providing scientific and strategic advice as a member of the board of PledPharma (Nasdaq First North), and Spago Nanomedical (Aktietorget, Stockholm).  Doctor Alain Herrera Dr. Alain Herrera, MD, PhD has contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. Oxaliplatin in combination with fluorouracil and leucovorin constitute one of today’s basic regimens, FOLFOX, in treatment of colorectal cancer. Currently Dr. Herrera operates as a Senior Consultant within the field of Oncology. Prior to this Dr. Herrera held the position of Vice President of Global Oncology Business Strategy and Development at Sanofi and before that he was Head of Global Oncology Franchise at Sanofi. Dr. Herrera has also served as Chairman of Chiron Therapeutics Europe and as Managing Director of Pierre Fabre Oncology Laboratories. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, Nanobiotix, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation. For more information, please contact: Anders Rabbe, CEO, Isofol Medical AB E­mail: anders.rabbe@isofolmedical.com Phone: +46 (0)707 646 500 About Modufolin® Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study. About Isofol Medical AB Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB. www.isofol.se

ROTTNEROS INTERIM REPORT JANUARY – JUNE 2017

· Production volume for the second quarter rose by 1% compared with the second quarter of 2016, despite the unplanned shutdown at Vallvik Mill, which entailed a production loss of about 4,500 tonnes. Rottneros Mill set a new quarterly production record once again. · Delivery volume for the second quarter rose by 7% compared with second quarter 2016. · Investments in the Agenda 500 development programme are progressing according to plan, in terms of both cost and increased capacity. · Rottneros Packaging is starting commercial production of fibre trays and will build a new production line. · Shareholders were paid a dividend of SEK 61 million in the second quarter. · Net turnover for the second quarter rose by 14% to SEK 472 million (413). For January-June, net turnover was SEK 944 million (845). · Profit after financial items for the second quarter totalled SEK 62 million (56) and for January-June SEK 118 million (125). Earnings per share for January-June were SEK 0.60 (0.65). · Cash flow from operating activities for the second quarter totalled SEK 53 million (52). · The list price for NBSK pulp over the second quarter was 8% higher in USD and 16% higher in SEK, compared with second quarter 2016. Compared with first quarter 2017, the price level in SEK was 4% higher.  COMMENTS BY THE PRESIDENT: YET ANOTHER QUARTER WITH PRODUCTION OVER 100 THOUSAND TONNES During the second quarter, the underlying trend of rising production rates continued in our mills. Operating profit increased by SEK 5 million despite some negative effects from unplanned items. We can see that the extensive investments within the framework of the Agenda 500 programme are paying off in higher volumes, even though the unplanned shutdown at Vallvik held back growth for the quarter as a whole. We steadfastly continue to take a structured approach to further improve safety and increase capacity utilization, thereby sustainably increasing volumes in our niches. Production rose by 1 per cent in the Group to 101,400 tonnes compared with last year’s second quarter, despite the negative impact of 4.5 per cent from the unplanned shutdown at Vallvik. In May, however, the mill achieved a record volume for a single month at the same time that Rottneros Mill demonstrated the highest production ever for a single quarter. These achievements confirm that we continue to clearly move upwards on the volume curve. Meanwhile, more remains to be done to increase availability and production in the future. Our goal-oriented efforts are also paying off in terms of operating profit, which rose by SEK 5 million compared with the second quarter last year to SEK 62 million, despite the negative impact of certain unplanned items amounting to approximately SEK 5 million and primarily related to the production shutdown at Vallvik. Conflict actions among social partners at the Port of Gothenburg also had a negative impact. Continued stable marketThe market continues to be stable with a good balance between supply and demand and we are cautiously optimistic in the run-up to the third quarter. At the end of the second quarter, the NBSK list price was USD 890, up about 7 per cent. However, new volumes coming from several Nordic players in the second half of the year and 2018 may have a negative impact on the market balance in the future. Our development area, Rottneros Packaging, is now approaching start of construction for the new production line for bio-based food trays in Sunne. Demand in the sustainable packaging solutions market is robust and we are optimistic about the development potential of this new segment. Key new hire at VallvikThe hiring of Michael Berggren as head of Vallvik Mill represents an important step for the further development of the mill. Although we have come a long way, much remains to be done in the development of the organisation. A constant effort to improve skills is crucial for increasing availability at the mills and leveraging our investments. Agenda 500Within the framework for the Agenda 500 programme, the Board of Directors has approved a total of approximately SEK 620 million, of which approximately SEK 460 million has been spent on implementing measures to date and measures for the remaining approximately SEK 160 million will be implemented in 2017 and 2018. The company has good liquidity. As previously announced, we are working with an extended long-term funding strategy, which ensures our ability to carry out the investment programme while changing the capital structure. Planning for the autumn maintenance shutdown is in full swing. Rottneros Mill carries out its shutdown in September and Vallvik plans to stop production in the beginning of the fourth quarter. The estimated cost of these shutdowns is SEK 10 million and SEK 55 million, respectively. We were pleased to see so many shareholders at the Annual General Meeting in Söderhamn. The opportunity to see our new investments at the tour of the mill in Vallvik definitely contributed to the strong attendance. In summary, it is clear that we have established a new level of availability and production volumes at the mills, creating continued growth opportunities, especially in our selected niches. Our focus is to continually optimise the factors we can influence, regardless of external factors. This is particularly important in light of potentially rising costs for our inputs such as wood and electricity in the future. We are becoming better equipped for the future, in terms of both meeting potential challenges and taking advantage of our opportunities. Lennart Eberleh (For full report, please see attached file) This information is information that Rottneros AB is obliged to publish under the EU Market Abuse Regulation and the Securities Market Act. This information was submitted for publication, through the agency of the contact person set out below, on 16 August 2017 at 8:00 a.m. A Swedish and an English version of this report have been drawn up. The Swedish version shall prevail in the event of differences between the two reports. For further information, please contact:Lennart Eberleh, CEO and President, Rottneros AB, +46 270 622 65

Swedbank acquisition of PayEx is approved by competition authorities and Swedish FSA

The market for payment solutions has undergone major changes in recent years by greatly increased on-line purchases and development of invoicing solutions and administrative services. Payment Service Providers (PSP), as PayEx, has been established with the purpose to improve the purchase experience. Through the approval of the acquisition of PayEx, Swedbank has the right prerequisites for continuing to invest in the payments area and continues to develop long term and attractive payment solutions for retail businesses and its customers. PayEx will be a fully owned subsidiary to Swedbank, with headquarters in Visby, Sweden, acting on an open market with both existing and new customers. The company will be consolidated as per 15 August 2017. In 2016 PayEx total operating income amounted to SEK 541m, total operating expenses to SEK 460m and profit before tax to SEK 78m. PayEx total risk exposure amount as per year-end 2016 was SEK 1.7bn. The acquisition will have a minor negative impact on the common equity tier 1 capital ratio of the Swedbank Group of approximately 40bps. For more information, please contact:Josefine Uppling, Group Press Officer, Swedbank, +46 761 14 54 21Gregori Karamouzis, Head of Investor Relations, Swedbank, +46 727 40 63 38 Information about PayExPayEx was founded 1972 by Max Hansson, who has owned the company since then. The company has more than 10 000 customers and approximately 500 employees in Sweden, Norway, Denmark and Finland. PayEx processes more than SEK 250 bn per year in their home markets on their customers´ behalf. PayEx has AAA-rating and is a credit market company, approved by the Swedish FSA. This announcement involves the disclosure of inside informationSwedbank AB (publ) is required to disclose this information pursuant to Regulation (EU) No 596/2014 on market abuse, the Swedish Securities Markets Act (2007:528), the Swedish Financial Instruments Trading Act (1991:980) and the regulatory framework of Nasdaq Stockholm. This information was sent to be published on 16 August, 2017 at 08.00 CET.

KID ASA – SECOND QUARTER 2017 RESULTS

Lier, 16 August 2017: The board of directors of Kid ASA has approved the financial report for the second quarter of 2017. Q2 HIGHLIGHTS (Figures from corresponding period the previous year in brackets) · Revenues of MNOK 278.4 (MNOK 265.5) in Q2 2017, an increase of 4.9%. Revenues were negatively affected by the timing of the Easter holiday in Q2 this year, whereas Easter was in Q1 last year. For the first two quarters of 2017, revenues amounted to MNOK 532.3 (MNOK 496.0), up 7.3% from 2016. The number of ordinary shopping days in the second quarter was 71 (75), and for the two first quarters the number of ordinary shopping days was 148 (149). · Like-for-like (LFL) sales increased by 2.8% (8.9%) in the quarter and 5.1% (2.6%) for first two quarters. · Gross margin of 61.6% (61.5%) in Q2 and 60.8% (60.0%) for the first two quarters. · EBITDA of MNOK 21.6 (MNOK 24.5) in Q2. For the first two quarters, EBITDA was MNOK 28.8 (MNOK 24.6). There were no EBITDA adjustments in the period from Q1 2016 to Q2 2017. · EPS decreased to NOK 0.19 (NOK 0.27) in Q2 2017, and increased to NOK 2.97 (NOK 2.20) for the past twelve months · The sale of home textiles in Q2 2017 in specialised stores in Norway increased by 7.7%, according to Statistics Norway. For the first two quarters of 2017, the corresponding figure was 7.0%. · New stores opened in Fornebu S (Oslo), Romerikssenteret (Kløfta) and Storo Storsenter (Oslo) during Q2. The stores at Sandvika Storsenter (Sandvika) and Glasshuset (Bodø) were relocated. The total number of physical stores at the end of the quarter was 137 (132). ENQUIRIESKjersti Hobøl, CEO Kid, +47 918 35 965Petter Schouw-Hansen, CFO Kid, +47 482 24 534

INCREASED SALES AND FURTHER FOCUSING OF BUSINESS OPERATION

SECOND QUARTER  · Net sales for the remaining operation totaled SEK 20.2 (18.9) million. · The operating profit for the remaining operation totaled SEK 0.5 (5.3) million. · Profit after tax for the remaining operation totaled SEK 0.2 (5.3) million. · Earnings per share for the remaining operation totaled SEK 0.00 (0.02). · Earnings per share for the total operation totaled SEK 0.00 (0.01). · Cash flow from total operations totaled SEK -1.3 (7.5) million. INTERIM PERIOD   · Net sales for the remaining operation during the interim period totaled SEK 36.8 (39.6) million. · The operating profit/loss for the remaining operation during the interim period totaled SEK -2.2 (12.4) million. · Profit after tax for the remaining operation totaled SEK -3.2 (12.4) million. · Earnings per share for the remaining operation totaled SEK -0.01 (0.04). · Earnings per share for the total operation totaled SEK -0.01 (0.03). · Cash flow from total operations totaled SEK 15.8 (17.5) million. Cash and cash equivalents for the total operation totaled SEK 115.0 (67.4) million at the end of the interim period.  SIGNIFICANT EVENTS   · An agreement was concluded with German company IDENTOS GmbH, which will take over the Mobile Smart Card Solutions business area as of January 1, 2018. · A new security suite was launched with industry-leading software for fingerprint recognition with spoof and liveness detection, as well as standalone anti-spoof products and services. · A licensing agreement was signed with Korean sensor manufacturer Melfas. After the end of the quarter, a licensing agreement was signed with module house O-Film. · Precise BioMatch™ Mobile was integrated into Qualcomm® Fingerprint Sensors, next-generation ultrasound-based fingerprint solutions from Qualcomm. · Seven mobile phones and two smart cards were launched with the company’s fingerprint software. FINANCIAL DATA AND KEY INDICATORS     As a consequence of the fact that the Mobile Smart Card Solutions business area has been classified as a business held for sale, previously reported figures have been converted in order to improve comparability. In order to obtain comparable historical data, previously reported figures have only been adjusted for expenses relating directly to the discontinued business area, which will no longer affect the company’s remaining operation. The resources that were previously allocated to the Mobile Smart Card Solutions business area will be transferred to the Fingerprint Technology business area before the divestment is completed and have therefore not been included in the divested business. Resources are being reinforced in order to meet the market’s demand for increasingly advanced solutions in the field of Fingerprint Technology. The impact of the discontinued operation on the financial position has not been reported separately, as the company does not believe that it is possible to report the impact of the discontinued operation on cash flow. Cash flow is instead reported from the total operation.Unless otherwise specified, reported figures in the interim report relate to the remaining operation. KEY INDICATORS  Amounts in 2017  2016  2017  2016  2016  Rolling SEK thousandunlessotherwisestated    Q2  Q2  Q1-Q2  Q1-Q2  Full 12 year  months Net sales   20,160  18,936  36,777  39,560  83,299  80,516 Net sales 6.5%  175.1%  Neg  282.9%  95.7%  12.2% growth, % Gross 95.0%  97.8%  94.7%  97.9%  98.0%  96.5% margin, % Operating 481  5,344  -2,179  12,402  25,407  10,826 profit/loss Operating 2.4%  28.2%  -5.9%  31.4%  30.5%  13.4% margin, % Operating -1,314  7,462  15,808  17,497  37,658  35,970 cash flow,totaloperationCash and 115,006  67,411  115,006  67,411  135,753  115,006 cashequivalents,totaloperation CEO COMMENTS  It is gratifying that we have increased sales during the quarter, both sequentially and compared with the corresponding period in the previous year. The partnership with Silead has resulted in substantial royalty revenues as Precise BioMatch Mobile has been launched in a number of phone models from one of the world’s biggest manufacturers. We now have royalty revenues from nine customers and continue to broaden the customer base in terms of both different technologies and geographical regions, in order to create good opportunities for growth and to reduce dependence on individual customer partnerships. We are also continuing to invest in development and support resources in Sweden and in the local markets in order to best support our customers.During the quarter we made a strategic decision to divest the loss-making Mobile Smart Card Solutions business area to IDENTOS in order to create a greater focus in the business. This divestment means that we can free up resources in both development and sales in order to strengthen our offering and our opportunities for growth in the field of fingerprint technology.There is currently a surfeit of sensor manufacturers offering capacitive sensors for fingerprint recognition. This has resulted in very tough competition with rapidly increasing demands for smaller sensors, better performance and lower prices, with suppliers that are already established enjoying competitive advantages. This makes it more challenging for many sensor manufacturers to break into the mobile phone manufacturers and capture bigger market shares. It is therefore more difficult to assess the sales volume of our customers during the second half of the year.At the same time we can see that new sensor technologies such as ultrasound and optical sensors are on the rise, which changes the market dynamics and opens the door for new suppliers. Ultrasound and optical sensors make it possible to integrate fingerprint sensors in and under the display, creating new design possibilities and lower product costs. There is a large interest in these kinds of solutions among mobile phone manufacturers. Many of our customers are offering ultrasound or optical sensors, which means that we are well positioned for the upcoming technology shift. We are working together with customers on several test projects, which we expect to result in product launches starting in the first half of 2018 and provide a further boost to our growth. For example, Qualcomm recently launched a new generation of ultrasound sensors and demonstrated the product in a modified version of VIVO XPlay 6 with our Precise BioMatch Mobile fingerprint software.We launched a new security suite during the quarter, offering industry-leading software for fingerprint recognition with the latest developments in spoof and liveness detection, as well as standalone anti-spoof products and services. The software is particularly suitable for optical and ultrasound sensors, and enhances security significantly for fingerprint recognition by identifying fake fingers and thereby combating fraud. The new solutions have generated a high level of interest among our customers and give us a unique position, as we are the only supplier that can offer software-based fingerprint software with spoof and liveness detection.Cards with fingerprint technology are on the rise. We announced two projects during the second quarter. Elan MicroElectronics launched a payment card with fingerprint technology that is to be supplied to premium customers of a South Korean bank. MeReal announced that their V2 biometric smart card will be put into use by Pleinair Casino. It is clear from work with our customers that the card market is developing quickly for both payments and other areas of application. We are involved in a number of card projects and are holding advanced discussions with several players in the card industry.OUTLOOKWe maintain our view on net sales for the remaining operation during 2017 and estimate that it will be on par with the comparable net sales for 2016 (SEK 83.3 million), even though the volume trend among our customers is more difficult to estimate than before. The company continues to expect an operating profit for the full year 2017 for the remaining operation.  PRESENTATION OF THE INTERIM REPORT           In connection with today’s interim report, we issue an invitation to an information event today at 10:00. Please see the last page of the interim report for further information about participation.  This information is information that Precise Biometrics AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8.00 CEST on August 16, 2017.

Biotage – alleged patent infringement settled

Scientific Plastic Products, Inc. (“SPP”) has brought claims for infringement of U.S. Patent Nos. 8,066,875 and 8,070,957, against Biotage et alt. in a civil action entitled Scientific Plastic Products, Inc. v. Biotage AB, et al. (“Defendants”), pending in the United States District Court for the Southern District of California (the “Lawsuit”). The matter has been amicably resolved and the Lawsuit has been dismissed. Defendants have not agreed to any liability and no claim remains pending against Defendants. The terms of settlement are confidential. Contact persons:Torben Jörgensen, CEOTel: 0707-49 05 84, torben.jorgensen@biotage.com This information is information that Biotage AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on August 16, 2017. About Biotage Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan and South Korea. Biotage has approx. 300 employees and had sales of 667 MSEK in 2016. Biotage is listed on the NASDAQ OMX Nordic. Website: www.biotage.com

FDA accepts Medivir´s IND application for MIV-711, enabling clinical development in the US

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the Investigational New Drug (IND) application for MIV-711 has been accepted and the IND is now open with the FDA (U.S. Food and Drug Administration). “We are very pleased to have received FDA acceptance for our IND. This is a regulatory milestone for MIV-711 and enables clinical development of MIV-711 in the US, in addition to the already completed and ongoing studies in Europe” says Åsa Holmgren, Medivir´s EVP Strategic Regulatory Affairs and Market Access. About MIV-711MIV-711 is being developed to slow or reverse the progressive degeneration of joints affected by osteoarthritis, and is therefore referred to as a Disease Modifying Osteoarthritis Drug (DMOAD). Since there are no DMOADs approved for use currently, the standard of care for osteoarthritis patients is based on changes in life style and the use of analgesics. The long-term use of analgesics by osteoarthritis patients is associated with an increased risk of side effects such as gastrointestinal bleeding and opioid dependency. DMOADs therefore represent a very large and attractive market opportunity. Medivir estimates that the US market alone is greater than USD 6 billion annually for a drug that impacts disease progression, even if its use was restricted just to patient populations with moderate osteoarthritis in weight-bearing joints. For further information, please contact:Ola Burmark, CFO Medivir AB, mobile +46 (0)725-480 580 About MedivirMedivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Episurf Medical reaches milestone of 250 implants

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by planning of its 250th surgery with the Episealer® implant in the coming weeks. “This milestone is very important for us, and at the same time, it is important to keep in mind that our clinical data is very strong and the patients are truly being helped by our technology. That said, it is obviously very encouraging that we have cut the time between our 50 intervals in half. Increasing our sales is important and this is a clear sign of the fact that the Episealer technology is gaining increased acceptance. This is a good day for Episurf Medical and I want to extend my gratitude to all orthopaedic surgeons, patients and employees“, says Pål Ryfors, CEO Episurf Medical. "It is reassuring to note that the orthopedic profession seems to catch on and note the good clinical results and the very few complications and adopt the Episealer technology. It starts to look as an exponential increase in users and usage of the Episealer device", says Prof. Leif Ryd, Senior Medical Advisor Episurf Medical. For more information, please contact: Pål Ryfors, CEO, Episurf Medical  Tel: +46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CET on 16 Augusti 2017.

SOTKAMO SILVER IS IN ADVANCED DISCUSSIONS ABOUT THE FINANCING OF THE SILVER MINE

Sotkamo Silver is in advanced discussions with a large international resources financing institution and the Swedish Export Credit Agency (ECA) for a comprehensive financing package, to fund the Engineering and Process Equipment (EPC) contract with Outotec and enable the mine to reach the production start. The discussions concerning terms and conditions are dependent on the guarantee decision of The Swedish Export Credit Agency (ECA). The discussions do not constitute a commitment or an offer to commit to any transaction or financing. The next step is the guarantee decision of the Board of the ECA. The decisions will be taken earliest on the 23rd August. Outotec provides leading technologies and services for the Sustainable use of Earth’s natural resources. “After the publishing of the Technical Report, the Company is fortunate to have multiple financing discussions going on, which is a market recognition of the quality of the Sotkamo Silver’s project. We are working with several options and are in advanced discussions with the resources financing institution and ECA”, says Dr Timo Lindborg, CEO Sotkamo Silver Stockholm August 16th, 2017 Sotkamo Silver AB (publ) This information is information that Sotkamo Silver AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:45 CEST on August 16th, 2017. Contact personTimo Lindborg, CEO of Sotkamo Silver AB, tel. +358 40 508 3507 The official Stock Exchange Releases are given in Swedish and there may be differences in the translated versions. About Sotkamo Silver AB Sotkamo Silver AB´s business concept is to exploit mineral deposits in the Nordic countries with positive social and environmental benefits. Sotkamo Silver owns mineral deposits, which contain silver and gold in Finland as well as zinc and gold in Norway. The Company’s main development project is the Silver Mine project in the municipality of Sotkamo. Sotkamo Silver applies SveMin’s & FinnMin’s respective rules of reporting for public mining & exploration companies. Sotkamo Silver has chosen to report mineral resources and ore reserves according to the internationally accepted JORC or NI 43-101 code. The company applies International Financial Reporting Standards (IFRS) as approved by the European Union. The ticker symbol is SOSI in NGM Equity in Stockholm and SOSI1 in NASDAQ OMX Helsinki. ISIN-code for Sotkamo Silver shares is SE0001057910. ISIN- code for share warrants series 2016/2017 are SE0008373880 with the ticker symbol SOSI TO4 in NGM Equity and SOSI1EW116 in NASDAQ OMX Helsinki. The number of outstanding warrants are 20,643,198. The Warrant gives the right to subscribe for one (1) share at 4 SEK in August 2017 Legal Entity Identifier (LEI): 213800R2TQW1OZGYDX93 Read more about Sotkamo Silver on www.silver.fi The Company's press releases and financial reports are distributed via Cision Sverige and are available on www.silver.fi

Saab delivers training systems to Estonian Army

The Estonian Armed Forces ordered the first laser simulators for gunnery and combat training in 2008. Saab has now received an additional order for simulators. The systems will be used by the mechanised brigade, at the regiments and at the infantry school. “I am proud that the Estonian Armed Forces have once again chosen Saab as their partner. They have used our training systems for quite some time and are very capable of seeing the benefits of realistic training. This order strengthens our position as one of the world’s leading suppliers of solutions for combat training”, says Åsa Thegström, head of business unit Training & Simulation at Saab business area Dynamics. The contract includes BT46 systems for the CV9035, Carl-Gustaf as well as several infantry simulators up to company level. For control and monitoring of exercises, Saab’s new Manpack 300 is used. Additionally, a five-year support contract is included. Through these upgrades, the Estonian Army is increasing its training capacity.     “This is very good, both for us and for the customer. With this order of BT46 training systems, the Estonian Armed Forces are obtaining the best simulator on the market for training both combat vehicle crews and mechanised units”, says Jyrki Kujansuu, head of country unit Poland & Baltics at Saab market area Europe. “With the support of the training system, the Estonian Armed Forces will be able to conduct both basic gunnery training from the CV9035 armoured combat vehicle and unit training up to the mechanised company level, cost-effectively and realistically. This will dramatically strengthen their units’ capacity in the field.” The BT46 system is proven and still the most modern simulator system for gunnery training with various weapons and for realistic, tactical combat exercises in the field. The system has already been delivered to more than 20 countries as support for combat exercises with vehicles and associated weapons systems. More than 7000 vehicle simulators have been delivered to over 100 applications worldwide. .   For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Schulthess Maschinen AG gets ready for the future by upgrading to IFS Applications 9

IFS Applications 9 empowers Schulthess Maschinen AG to cover many of its new requirements without the need for significant customizations. A key feature of IFS Applications 9 is IFS Lobby, which is a personalized interface into the solution appropriate not only to the users’ level and role but also their personal preferences. The modern layered architecture of IFS Application 9 enables Schulthess Maschinen AG to perform updates easily and quickly so that the company can continue to operate on the latest version of the software. Having used IFS Applications for over a decade, the upgrade to IFS Applications 9 will continue to support business critical processes like: finance, sales and support, engineering, production, logistics, service management and maintenance. In addition, Schulthess Maschinen AG will now also utilize IFS Warehouse Data Collection, a mobile solution for automation of inventory management. In a preliminary project, IFS and Schulthess Maschinen AG analyzed the company’s individual customizations of IFS Applications 7 to define which need to be lifted, which are covered by the standard deployment of IFS Applications 9, as well as which were obsolete. This way, the number of customizations Schulthess Maschinen AG will migrate to IFS Applications 9 will be reduced by around half. “We are glad to continue our longstanding and trusted partnership with IFS”, Schulthess Machinen AG CFO, Martin Keller, said. “Upgrading to IFS Applications 9 is a big and important technological step for the digital future of our company. The layered architecture of IFS enables us to run our solution in an ‘evergreen’ mode so that it is continuously up-to-date.” “We’re honored by the continued trust of Schulthess Maschinen AG in IFS”, Guido Zumstein, Managing Director of IFS in Switzerland, added. “It’s not only testament to our future-proof technology but it also confirms our approach to accompany customers as a longstanding partner supporting their successful corporate development with our comprehensive industry expertise.” More information on the IFS solutions for the industrial manufacturing: http://www.ifsworld.com/corp/industries/industrial-manufacturing/

Nordic Nanovector ASA: Invitation to Second Quarter 2017 Results Presentation and Webcast

Oslo, Norway, 16 August 2017 Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for haematological cancers, will announce its second quarter 2017 results on Wednesday, 23rd of August 2017. A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: BJØRVIKA The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2017 from 7:00 am CEST the same day. For further information, please contact:IR enquiries:Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com MediaEnquiriesMark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson)Tel: +44 207 638 9571Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com

TROAX: INTERIM REPORT JANUARY – JUNE 2017

APRIL – JUNE 2017 · Order intake increased by 30 per cent to 39,8 (30,5) MEUR. Adjusted for acquisition and currency the increase was 17 per cent. · Sales increased 40 per cent to 39,6 (28,3) MEUR. Adjusted for acquisition and currency the increase was 26 per cent. · Operating profit increased to 8,2 (5,1) MEUR. · Operating margin increased to 20,7 (18,0) per cent. · Financial net was -3,4 (-0.9) MEUR of which -2,3 MEUR is related to a one-time cost related to the redemption of the bond. · Profit after tax increased to 3,7 (3,1) MEUR. · Earnings per share was 0,19 (0,16) EUR. JANUARY – JUNE 2017 · Order intake increased by 31 per cent to 78,3 (59,6) MEUR. Adjusted for acquisition and currency the increase was 17 per cent. · Sales increased 38 per cent to 75,9 (55,1) MEUR. Adjusted for acquisition and currency the increase was 22 per cent. · Operating profit increased to 14,8 (9,8) MEUR. · Operating margin increased to 19,5 (17,8) per cent. · Financial net was -4,6 (-1,8) MEUR of which -2,3 MEUR is related to a one-time cost related to the redemption of the bond. · Profit after tax increased to 7,7 (5,9) MEUR. · Earnings per share was 0,39 (0,30) EUR. CEO COMMENTS  Troax has developed well during the second quarter with an organic increase in orders of 17%, which clearly is above the historical growth average. We have received several important orders from customers within, automotive, warehouse and property, which shows that the Troax offering is strong. The newly acquired company in the USA, Folding Guard is following their plans and has a favorable trend in orders received. Our judgment is that the market development during the second Quarter has been positive for the Group. The growth has been especially strong in Continental Europe, and also new Markets have had a positive quarter. In the UK, we have during the second quarter seen some negative effects of a weaker willingness to invest at some customer groups, probably caused by the uncertainty related to Brexit etc. The orderbook at the end of the quarter continues on a good level. The integration work of the acquired company (end of last year), Folding Guard is progressing well. During the second quarter, the Nashville warehouse has been closed and the distribution moved to Chicago. The focus on growth continues to be strong but is not expected to show any bigger impacts until 2018/19. We can again confirm that the acquisition has so far been well received by important customers in the US. We see good opportunities to strengthen the customer base, long term, for both brands in the important market of North America. Sales invoiced increased in the quarter by 40 per cent compared with the same period last year (excluding acquisition and currency the increase is 26 per cent). The progress was positive in all markets. Totally, the Group has increased to an order intake level of approximately 138 MEUR on a rolling 12 month basis (including Folding Guard for the first two quarters of 2017). The result has continued to improve during the quarter, mainly because of good sales volumes and the consequential good capacity utilization in our factories. During last year, we also had some one-time costs related to the inauguration of the new paint line which we do not have this year. The market investments are continuing per plan. This is at a lower level short term, as some internal resources have been dedicated to the integration of our American acquisition. The operating result was 8,2 (5,1) MEUR, which corresponds to a profit margin of 20,7 per cent to be compared with 18,0 per cent last year. It should be noted that the consolidation of Folding Guard decreases the margin in percentage terms. We do however see clear possibilities to increase the margin also for Folding Guard long term. The Net result has also developed in a positive way, and amounts to 3,7 MEUR for the quarter (3,1 MEUR). In this comparison, we must consider that we have had a one-time financing cost of -2,3 MEUR related to the redemption of the bond in order to move over to ordinary bank financing. Barring any other eventualities, this change in the company’s financing structure will improve the finance net by 3,4 MEUR annually from now onwards. The result per share after the first half year is 0,39 EUR to be compared with 0,30 EUR last year. The Working Capital is on a similar level as the previous quarter. Work in Progress is on a continued high level, indicating that some important projects still are under implementation and hence still have not been invoiced.  We have continued with good cash generation from operations during the quarter and the net debt is now 66,5 MEUR and the key figure of our interest-bearing loan in comparison with EBITDA is below our target for the Group. Thomas Widstrand, President and CEO PHONE CONFERENCE Invitation to presentation of the second quarter result:Thomas Widstrand, CEO presents the result on a phone conference on the 16th of August 2017 at 16:00 CET. The conference will be held in English. For more information, please refer to http://www.troax.com/en/news. This information is information that Troax Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014 and the Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person set out above, at 12:30 CET on 16th of August, 2017.

Talkpool Interim report January – June 2017

APR 1st – JUNE 30th 2017 ·Net sales amounted to EUR 3 441 thousand (2 653), a 29.7 percent increase ·EBITDA of EUR 86 thousand (-9) and EBITDA margin of 2.5 percent (-0.3) ·EBIT of EUR 67 thousand (-20) and EBIT margin 2.0 percent (-0.8) ·Loss after tax of EUR -116 thousand (84). ·Cash flow from operating activities amounted to EUR 158 thousand (51) JAN 1st – JUNE 30th 2017 ·Net sales amounted to EUR 6 896 thousand (5 109), a 35.0 percent increase ·EBITDA of EUR -44 thousand (75) and EBITDA margin of -0.6 percent (1.5) ·EBIT of EUR -80 thousand (55) and EBIT margin -1.2 percent (1.1) ·Loss after tax of EUR -305 thousand (-65). ·Cash flow from operating activities amounted to EUR 167 thousand (72) APRIL - JUNE HIGHLIGHTS ·Talkpool acquired LCC Pakistan with 1,000 employees and EBITDA of around EUR 1.5 million ·Talkpool’s Group EBITDA went from an operative loss of EUR -130 thousand in Q1 2017 to a profit of EUR 86 thousand in Q2 2017 ·Talkpool’s new growth-through-M&A Strategy proved successful as the newly acquired companies Camouflage and Technetix contributed significantly to the positive financial development ·European network operators such as Deutsche Telekom, Belgacom, Vodafone and Orange became the fastest growing client segment for TalkPool ·TalkPool became a Deutsche Telekom entrusted partner for FTTH projects in eastern Germany ·Talkpool Mexico’s investments in staff hiring, training and tools paid off as the company reached break even ·Talkpool AG and Sigren Engineering AG were awarded an IoT smart building assignment for real estate in Zürich CEO COMMENTS The positive Q2 report comes as no surprise. The positive trends in terms of revenue, profits and cashflow continue. Talkpool reports an EBITDA profit (of EUR 86 thousand) for the first time since its IPO. The newly acquired companies Camouflage and Technetix are developing well at the same time as Talkpool continues its positive organic development. The revenue growth continues and many of our markets developed well, with additional contracts and increasing orders. In addition to the positive organic development of our business, the newly acquired companies Camouflage and Technetix performed well in Q2. Camouflage almost doubled revenues from Q1 to Q2 and more than six-folded its profit. Camouflage was in the closing phase of an important operation & maintenance contract in June. It is a long term contract, similar to the one in Haiti, with recurring orders and a revenue stream that is valuable for the financial stability and growth of the company. Technetix in Belgium continued with solid revenue in Q2, in line with Q1, and managed to more than double the profit compared to Q1. The positive order trend from European network operators such as Deutsche Telekom, Belgacom, Vodafone and Orange continued in Q2.  Growth through M&A The acquisition of LCC in Pakistan that has 1,000 employees and EBITDA of around EUR 1.5 million for latest financial year, is a significant event in Talkpool’s history and a giant leap in the company’s growth development. After consolidating LCC into the Group, we are expecting to double revenues, improve EBITDA margins and reach a positivestrengthen our operative cashflow. We’re planning to develop LCC Pakistan into the company hub for the Middle East. The LCC acquisition accelerates Talkpool’s transformation into a profitable and fast-growing business that stands on its own feet. We have now achieved the first step in our strategic roadmap and through this we have gained the financial and operational stability to increase the investments in the emerging Internet of Things industry. Growth through M&A has turned out successful with the first two acquisitions of Technetix and Camouflage. In addition to the significant financial contribution those acquisitions also add new knowledge, customer segments and geographical regions to Talkpool Group. The added value will become even more obvious as LCC Pakistan is added to the group. Furthermore, know- how is also being gained by analzying the market and the different acquisition target companies. Based on this success we will continue on our acquisition path for both network services and IoT. Organic growth in many regions Talkpool Mexico had a slow startofin2017 Q1 with very little project activities due to a combination of seasonality and the Trump effect, but in Q2 the market started moving again and Talkpool Mexico’s investments in staff hiring, training and tools started to pay off. Our activities in Germany also continued to gain speed in Q2. Talkpool is now an established provider of broadband network design and project management services to Deutsche Telekom in the big government-sponsored fiber build-out in Germany. The federal government in Germany plans to roll out a gigabit internet service across the country by 2025. The EUR 100 billion project will focus on bandwidth, security and response times. The development, including virtual reality and the internet of things, will bring huge data growth and the need for more bandwidth, reliable real-time transmission and intelligent networks. Haiti and Tanzania continued to deliver stable and reliable revenue and profits and the outlook is good in both countries. Digicel in the Caribbean issued a request for quotation for the operation and maintenance in Haiti and other major markets in the region and Talkpool is very well positioned to extend the contract for the existing region and expand into new areas. IoT Talkpool AG and Sigren Engineering AG were awarded an IoT smart building assignment for real estate in Zürich, Switzerland that hosts a large search engine company and other prime tenants. The project is considered strategically important. The sales of Talkpool´s IoT temperature and humidity sensors continued to develop very well and the new partner contract with Avnet Silica will contribute very positively to this trend. The IoT market has not developed as expected and until now we have not had any major break through although we are well positioned in the market and have many good customer relations and prospects. We will continue investing in in-house R&D and organic growth, in particular in the key verticals Smart Building and Environmental Supervision. Based on the successful acquisitions in the Network Services area we think that growth through M&A is the way forward in the area of IoT as well and Talkpool is looking at interesting targets.  Continuous efforts improve profitability Talkpool managed to generate a net sales growth from EUR 2 653 thousand in Q2 2016 to EUR 3 441 thousand in Q2 2017 which corresponds to a of 29,7 percent increase. The large increase is mainly explained by the acquisition of Camouflage and Technetix, contributing with net sales in profitable niche network services areas of approximately EUR 752 thousand in Q2 2017. In addition to this, the investments made to fuel the growth in Mexico and Germany showed result and revenue continued to steadily increase throughout the quarter. Thanks to reductions in cost of sales, Talkpool increased the gross profit with approximately 25 percent compared to Q1 2017 and 49 percent compared to Q2 2016. The focused and conscious efforts to reduce SG&A costs continued to bear fruit in Q2. In spite of being in the middle of Talkpool’s biggest acquisition ever, we managed to reduce the SG&A costs with another 6.5 percent in Q2 compared to Q1. In Q2 2017 EBITDA turned positive with EUR 86 thousand compared to an EBITDA of EUR -129 thousand in Q1. This is mainly explained by lower costs of sales and SG&A costs. The newly acquired companies, Camouflage and Technetix, even reached gross margins of over 30 percent. Also the previously loss making growth markets Mexico and Germany both left “the red zone” and reached break even at the end of Q2. EBIT for the group in Q2 reached EUR 67 thousand. Although EBITDA and cashflow turned positive in Q2, net earnings remained below zero. The net loss amounted to EUR -116 thousand mainly due to unusually high exchange losses on cash and bank accounts. The cash flow from operating activities was positive despite a negative result for Q2 and the total cash flow for Q2 2017 was positive by EUR 1 322 thousand mainly due to increase in borrowings. Q3 started off well as Camouflage signed the important operation & maintenance contract and Talkpool and its partners were awarded the prestigiuos IoT project for environmental monitoring in West Sweden where Talkpool will have a prominent role. Erik Strömstedt, CEO     FOR FURTHER INFORMATION, PLEASE CONTACT: Erik Strömstedt, CEO Telephone: +41 79 790 60 40     erik.stromstedt@Talkpool.comHanna Rubensson, CFO    Telephone: +46 73 140 48 40   hanna.rubensson@Talkpool.com This information is such information as TalkPool is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the contact person below for publication on 16 august 2017 at 13:30 CET.THIS IS TALKPOOL Talkpool builds, maintains and improves telecommunication networks globally. Through its cutting-edge technical expertise, long experience and agile business model, Talkpool offers global telecom vendors and operators high-quality services on short notice no matter the location. Moreover, Talkpool is one of few companies with actual solutions and contracts in place in the exciting IoT-market.

Acando acquires Daytona and Transformator Design

”The Acando Group continues to execute on our strategy “Technology Driven - Behavior Centric” says Carl-Magnus Månsson, CEO, Acando Group. ”With the acquisition of Daytona and Transformator Design, and a strong positive development at Acando and itch, we now take a leading position in the Northern European market.”   Combining the capabilities of Transformator Design and Daytona with Acando’s units specialized in strategy, transformation and digital development as well as Acandos’s innovation agency itch, will create a strong range of offerings within customer experiences. The new business will combine empathy and deep understanding for human needs with innovative and technical solutions. ”We started the design and -innovation agency itch almost two years ago, and we’re now taking the next step by creating a full-fledged Business Design Studio. We’ve acquired two of the best agencies in the field and by combining the competence of their teams with Acando’s and itch’s strategists, user experience designers and developers, we will be Sweden’s leading Business Design Studio from day one” says Mats Alerius, Senior Vice President, Acando. ”We’ve seen a strong demand for itch’s services, not least when combined with Acando’s strong ability to drive transformational change. The acquisitions give us both new width and depth in terms of capabilities, but we will also be able to create new and unique offerings” says Martin Deinoff, CEO, itch. The merge is initiated immediately and will continue throughout the coming months. There are similar existing operations in Norway and Germany within Acando, and further expansion plans are being evaluated. “Transformator Design is the one agency that has come to be most clearly associated with the Service Design-sector in Sweden. We now take a new exciting step entering a new context. Putting the human at the center is becoming continuously important for companies and organizations and they are looking for a partner with deep understanding of human needs as well as the capability to make change happen. As part of Sweden’s largest Business Design Studio with Acando as owner, we will to an even bigger extent than before, be able to contribute to a more human society using design as a tool” says Daniel Ewerman, CEO, Transformator Design. ”It’s not enough to just be able to talk about and design solutions today. You must also be able to actually realize strategies and concepts, through user-driven prototyping and with technique as a driver. That is something we have missed at Daytona during the last years – to be able to actualize ideas and to prototype to a deeper level” says Martin Ragnevad, CEO Daytona.

YIT to start the construction of a new apartment building project in the Moscow region, Russia

YIT starts the construction of a new apartment building project in Lytkarino, Moscow Region, Russia. The project will comprise approximately 200 apartments as well as business premises. The total value of the project is approximately EUR 10 million and the start-up is recorded in the third quarter. The project will be completed by the end of summer 2019. The project is the latest phase of an area development project called Microdistrict 4A and it has an excellent location with a panoramic landscape to the Moscow River. A lake with a beach and a forest park area are also located nearby in the environmentally friendly area. The area is easily accessible via the Moscow Ring Road which is approximately 10 kilometres away along with good public transportation connections. The apartments vary from two and three room standard apartments with spacious living rooms to compact studio apartments. For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi  Teemu Helppolainen, Head of Business Area, Russia, YIT Construction Ltd, tel. +7 915 316 8216, teemu.helppolainen@yit.ru  YIT CORPORATION Hanna JaakkolaVice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT creates better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life in sustainable cities. We want to focus on caring for customer, visionary urban development, passionate execution and inspiring leadership. Our growth engine is urban development involving partners. Our operating area covers Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2016, our revenue amounted to nearly EUR 1.8 billion, and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki. www.yitgroup.com  Disclaimer Notice to Lemminkäinen Shareholders in the United States The YIT shares to be issued in connection with the merger of YIT and Lemminkäinen have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and are being issued in reliance on the exemption from registration set forth in Rule 802 under the Securities Act. YIT and Lemminkäinen are Finnish companies and the issuance of YIT shares will be subject to procedural and disclosure requirements in Finland that may be different from those of the United States. Any financial statements or other financial information included in this investor news may have been prepared in accordance with non-U.S. accounting standards that may not be comparable to the financial statements of U.S. companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States. It may be difficult for U.S. shareholders of Lemminkäinen to enforce their rights and any claims they may have arising under U.S. federal securities laws in connection with the merger, since YIT and Lemminkäinen are located in non-U.S. jurisdictions, and some or all of YIT’s and Lemminkäinen’s officers and directors may be residents of countries other than the United States. As a result, U.S. shareholders of Lemminkäinen may not be able to sue YIT or Lemminkäinen or their respective officers and directors in a court in Finland for violations of U.S. federal securities laws. Further, it may be difficult to compel YIT or Lemminkäinen to subject themselves to the jurisdiction or judgment of a U.S. court. Lemminkäinen’s shareholders should be aware that YIT may purchase Lemminkäinen’s shares otherwise than under the merger, such as in open market or privately negotiated purchases, at any time during the pendency of the proposed merger.

Pihlajalinna Half Year Financial Report 1 January–30 June 2017 (6 months)

Pihlajalinna Plc     Half Year Financial Report     17 August 2017 at 8.00 a.m. Pihlajalinna Half Year Financial Report 1 January–30 June 2017 (6 months) Soft second quarter for Private Clinics and Specialised Care, strong profitability in Primary and Social Care Brief look at April–June: ·  Revenue amounted to EUR 106.7 (101.4) million – an increase of 5 per cent  ·  EBITDA amounted to EUR 7.1 (7.0) million  ·  Adjusted EBITDA amounted to EUR 7.4 (7.0) million – an increase of 6 per cent  ·  Operating profit (EBIT) amounted to EUR 3.7 (3.5) million  ·  Adjusted operating profit (EBIT) amounted to EUR 4.0 (3.9) million – an increase of 2 per cent  ·  Earnings per share (EPS) was EUR 0.10 (0.10)  Brief look at January–June: ·  Revenue amounted to EUR 216.7 (201.4) million – an increase of 8 per cent ·  EBITDA amounted to EUR 16.0 (14.0) million ·  Adjusted EBITDA amounted to EUR 16.5 (14.0) million – an increase of 18 per cent ·  Operating profit (EBIT) amounted to EUR 9.1 (7.7) million ·  Adjusted operating profit (EBIT) amounted to EUR 9.7 (8.1) million – an increase of 20 per cent ·  Number of personnel at the end of the reporting period was 4,898 (4,589) ·  Earnings per share (EPS) was EUR 0.25 (0.19) KEY FIGURES AND RATIOS 4–6/2017 4–6/2016 1–6/2017 1–6/2016 2016 3 mths  3 mths  6 mths  6 mths  12 mthsINCOME STATEMENTRevenue, EUR million 106.7 101.4 216.7 201.4 399.1EBITDA, EUR million 7.1 7.0 16.0 14.0 27.9EBITDA, % 6.7 6.9 7.4 7.0 7.0Adjusted EBITDA, EUR 7.4 7.0 16.5 14.0 28.9millionAdjusted EBITDA, % 6.9 6.9 7.6 7.0 7.2Operating profit (EBIT), 3.7 3.5 9.1 7.7 15.1EUR millionOperating profit, % 3.5 3.5 4.2 3.8 3.8Adjusted operating 4.0 3.9 9.7 8.1 16.6profit (EBIT), EURmillionAdjusted operating 3.7 3.9 4.5 4.0 4.2profit, %Profit before tax (EBT), 3.3 3.1 8.3 6.9 13.7EUR million SHARE RELATEDINFORMATIONEarnings per share 0.10 0.10 0.25 0.19 0.39(EPS), EUREquity per share, EUR 4.84 4.66 4.74 OTHER INFORMATIONReturn on capital 10.6 7.1 10.8employed (ROCE), %Return on equity (ROE), 11.8 6.8 11.1%Equity ratio, % 44.7 45.4 46.5Gearing, % 32.4 33.9 21.9Interest-bearing net 33.5 33.4 22.1debt, EUR millionNet debt/adjusted 1.1 1.6 0.8EBITDA, 12 mthsGross investments, EUR 3.1 10.4 7.8 20.8 27.4million*Cash flow from operating 0.8 -4.6 14.3 9.3 32.3activities, EUR millionCash flow after -1.4 -11.2 8.0 -7.3 6.8investments, EUR millionAverage number of 3,812 3,450 3,503personnel (FTE)**Personnel at the end of 4,898 4,589 4,407the period * Finance leases are not included in the gross investments** Pihlajalinna has transitioned to reporting the number of personnel on average as full-time equivalents (FTE) instead of the previous Average number of personnel indicator. Aarne Aktan, CEO of Pihlajalinna: Pihlajalinna’s second quarter of 2017 fell slightly short of our expectations. The organic growth of 2.5 per cent in revenue was mediocre, and there was room for improvement in profitability. The second quarter was a strong one in the Primary and Social Care (P&S) segment. The profitability of Social and Healthcare Outsourcings improved as expected, and the profitability of Other Business Operations was better than expected. The second quarter was soft in the Private Clinics and Specialised Care (C&S) segment. The profitability of the segment was weakened by Private Clinics, Public Specialised Care as well as Dental Care. The profitability of Occupational Healthcare was gratifying. In digital services, Pihlajalinna’s remote doctor application has met with a favourable reception. We will continue our investments so that we will be able to launch new digital services and products during the rest of the year. After the end of the reporting period, we made three acquisitions supporting our strategy. We reinforced our imaging network to improve the care chain of our customers, acquiring the imaging companies Joen Magneetti and Sataman Röntgen in Joensuu and Kuopio, respectively. In Oulu, we acquired Caritas Lääkärit Oy to strengthen the start of our future new private clinic in the city. The acquisition supports our expansion in terms of both personnel and customer accounts. In May, the municipal councils of Forssa, Humppila and Ypäjä voted in favour of establishing a joint venture with Pihlajalinna to provide social and healthcare services for the region. The decisions have been appealed to the Market Court. The municipal boards of Forssa and Humppila have proposed in August to the municipal councils to revoke the procurement decision and to suspend the procurement procedure. The procurement decision made by the municipality of Hattula on its social and healthcare services was repealed by the Market Court in June, so the previously announced agreement will not be implemented. In Tervola, where we had already been chosen as a service provider, we unfortunately did not reach an agreement with the municipality on the production of social and healthcare services and their costs. We do not consider the postponement of the health, social services and regional government reform by one year to be a major issue in the scale of the reform as a whole. We firmly believe that the health, social services and regional government reform will be realised during this government term. The postponement, on the other hand, may refresh the municipal outsourcing market. Pihlajalinna’s outlook for 2017 unchanged Pihlajalinna’s revenue is expected to grow and adjusted operating profit (EBIT) to improve compared to 2016. In the financial year 2016, revenue was EUR 399.1 million and the adjusted operating profit (EBIT) was EUR 16.6 million. Financial reporting in 2017 Interim report January–September: Thursday 9 November 2017 Briefing Pihlajalinna Plc will hold a briefing for analysts and the media on Thursday 17 August 2017 at 10:00 a.m. in the Paavo Nurmi room at Hotel Kämp, Pohjoisesplanadi 29, 00100 Helsinki, Finland. Helsinki, 16 August 2017 Pihlajalinna Plc’s Board of Directors

INTERIM REPORT NEW WAVE GROUP AB

PERIOD 1 APRIL – 30 JUNE 2017 ·  Sales amounted to SEK 1,372 million, which was 9 % higher than last year (SEK 1,257 million). ·  Operating result amounted to SEK 110.5 (100.2) million. ·  Result for the period amounted to SEK 77.0 (67.0) million. ·  Earnings per share amounted to SEK 1.16 (1.01). ·  Cash flow from operating activities amounted to SEK 50.1 (88.6) million. PERIOD 1 JANUARY – 30 JUNE 2017 ·  Sales amounted to SEK 2,636 million, which was 10 % higher than last year (SEK 2,388 million). ·  Operating result amounted to SEK 153.7 (108.3) million. ·  Result for the period amounted to SEK 101.9 (62.4) million. ·  Earnings per share amounted to SEK 1.55 (0.95) kr. ·  Cash flow from operating activities amounted to SEK 83.7 (152.5) million. ·  Equity ratio amounted to 48.6 (45.8) %. ·  Net debt to equity ratio amounted to 61.7 (75.2) %. CEO COMMENTS April – JuneOur growth continues and sales increased 9 % including currency to SEK 1,371.7 million, which is a record for a second quarter. It is the 12th consecutive quarter of growth which we are proud of. Operating profit increased by 10 % to SEK 110.5 million, which is strong in view of the substantial investments we make in both new products and marketing. These are strong figures, especially as we expected a negative calendar effect in this quarter due to the fact that Easter occurred during the second quarter of this year. The balance sheet remains very strong, with an equity ratio of 48.6 %, and we also have a positive cash flow in spite of growth.  January – JuneSales increased by 10 % to SEK 2,635.9 million, which is an all-time high. There was also an operating profit increase of 42 % to SEK 153.7 million and profit after tax increased by a whole 63 % to SEK 101.9 million. Delightedly, all regions and all segments are showing growth. We also continue to grow with a positive cash flow, resulting in a very strong balance sheet where we reduced our net debt, have a low debt/equity ratio and an equity ratio of 48.6 %. The operating margin also improved compared with last year and amounted to 5.8 (4.5) %. The futureWe are now faced with some really exciting quarters and years. CRAFT Teamwear is now starting to take off and we have signed PEC Zwolle, the Finnish floorball association, Warberg Floorball Club and Lycurgus Volleyball Club, among other elite clubs and teams. We will over the next few quarters add additional clubs in Europe. At the end of August we will open our new Canadian warehouse for Cutter & Buck and Clique. We have also made a decision on new warehouses in Germany and Belgium and to automate parts of the warehouse in Italy. Right now, and even in January 2018, we will launch a record number of new products for ProJob and Jobman. In the first quarter of 2018, CRAFT shoes will also be out in the shops. Even Kosta is developing well and we will continue our investments there. We will also, as we previously reported, be starting extensive marketing in the USA at the end of this and next year. With everything that we’ve done, and everything that we do, we are well equipped and we will definitely continue our growth. In terms of earnings, I believe in continued growth. There can of course be single quarters which have lower growth, particularly if a lot of establishment costs end up in the same quarter. But we have now managed to achieve sales growth in 13 of the last 14 quarters, and improved operating profit in 11 of them. Even our operating result has improved significantly since we started our major investments for the future in 2014. From SEK 255 million 2015 to SEK 400 million 2016, and now on a rolling 12 months to SEK 445 million. There is a strong trend in terms of both sales and result. We stand strong in for the future and our journey has just begun! Torsten Jansson, CEO      FOR MORE INFORMATION, PLEASE CONTACT: CEO Torsten JanssonPhone: 031–712 89 01E-mail: torsten.jansson@nwg.se  CFO Lars JönssonPhone: 031–712 89 12E-mail: lars.jonsson@nwg.se  The information in this report is that which New Wave Group AB is required to disclose under the Securities Exchange and Clearing Operations Act and/or the Financial Trading Act. The information was released for publication at 7 am (CET) on 17 August 2017.

Ambea AB (publ) today announces that Patrik Attemark, Business Area Head of Nytida, is leaving the company

Fredrik Gren, President and CEO, Ambea AB: “Over the past year we have worked successfully to integrate Solhagagruppen, but to deliver on Nytida’s full growth and profitability potential, we have reached the conclusion that there is a need for a new leadership in the business area. I would therefore like to extend my gratitude to Patrik for his time at Ambea and wish him the best of luck”. Patrik Attemark will leave Ambea in August and the recruitment process has commenced. Agneta Lindgren who has been long standing Business Area Head of Nytida and now lately Head of Norway, assumes the role as acting Business Area Head during the recruitment process. For more information, please contact: Louise Tjeder, Head of IR and Strategy Phone: +46 73 143 17 68 E-mail: louise.tjeder@ambea.se Nanna Wedar, Director Communications Phone: +46 70 166 58 88 E-mail: nanna.wedar@ambea.se This information is information that Ambea AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on August 17, 2017.  Ambea, is present in care services, and has approximately 14,000 employees. We offer services in disabled care, individual and family care, and elderly care with a focus on residential care and own management. We aim to be the quality leader in all that we do and our vision is to make the world a better place, one person at a time. At the end of the second quarter of 2017, Ambea had approximately 6,200 beds and 2,000 school and daily operation placements at around 500 units in Sweden and Norway. Total revenue and adjusted EBITA for the 2016 financial year amounted to SEK 5,409 million and SEK 456 million, respectively. The company was founded in 1996, is headquartered in Solna and is listed on Nasdaq Stockholm.  

Ambea interim report January-June 2017

The growth in net sales of 7 per cent was driven by increased sales under own management, while the contract management operations declined compared with the year-earlier period. The share of total sales under own management amounted to 64 per cent (59) compared with the year-earlier period, an increase attributable to minor acquisitions and start-up units. Our staffing operations also continued to grow with improved profitabaility. The future organic growth of our operations under own management was strengthened during the quarter through the addition of 243 new, signed and commenced beds/place­ments, giving Ambea a record-breaking pipeline of 844 beds/ placements at the end of the quarter. Following the IPO on 31 March, we resumed our acquisition activity, which resulted in the acquisition of the LSS company Resursteamet as well as a minor acquisition in Norway after the end of the quarter”. Highlights of the first quarter: · Net sales rose 7 per cent to SEK 1,442 million (1,352) · Adjusted EBITA, excluding items affecting comparability totalling SEK -6 million (-29), increased 15 per cent to SEK 110 million (96). The adjusted EBITA margin was 7.6 per cent (7.1) · EBITA and adjusted EBITA were impacted positively in an amount of SEK 18 million attributable to a repayment of previously paid pension premiums · Profit for the period amounted to SEK 20 million (13) · Earnings per share before and after dilution totalled SEK 0.3 (0.2) · Operating cash flow amounted to SEK 118 million (80) · Free cash flow totalled SEK 80 million (58) · 243 new signed/commenced beds/placements in the quarter adds up to a total of 844 at the end of the quarter Telephone conference: Ambea will host a presentation with the possibility to attend through a telephone conference at 10:00 (CET) today. The presentation will be held in English and will also be available as webcast on: http://edge.media-server.com/m/p/asztjnii Dial-in information: To ensure that you are connected to the conference call, please dial in a few minutes before the conference call to register your attendance by stating “Ambea”.   Dial-in numbers: Sweden:                             +46 (0) 8 5065 3936 UK:                                     +44 (0) 20 3427 1906 US:                                     +1 212 444 0896 The interim report, presentation and other material are available on www.ambea.com For more information, contact: Louise Tjeder, Head of IR and StrategyTelefon: +46 731 43 17 68E-post: louise.tjeder@ambea.se Nanna Wedar, Director CommunictationsTelefon: +46 70 166 58 88 E-post: nanna.wedar@ambea.se This information is information that Ambea AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on August 17, 2017.  Ambea, is present in care services, and has approximately 14,000 employees. We offer services in disabled care, individual and family care, and elderly care with a focus on residential care and own management. We aim to be the quality leader in all that we do and our vision is to make the world a better place, one person at a time. At the end of the second quarter of 2017, Ambea had approximately 6,200 beds and 2,000 school and daily operation placements at around 500 units in Sweden and Norway. Total revenue and adjusted EBITA for the 2016 financial year amounted to SEK 5,409 million and SEK 456 million, respectively. The company was founded in 1996, is headquartered in Solna and is listed on Nasdaq Stockholm.

Interim Report 1 January – 30 June 2017

3 months ended 30 June 2017 · Local currency sales increased by 11% and Euro sales increased by 12% to €347.6m (€309.6m). · Number of registered actives decreased by 2% to 2.8m. · EBITDA amounted to €47.9m (€40.6m). · Operating margin was 11.7% (9.9%), favourably impacted by 40 bps from currencies, and operating profit was €40.5m (€30.8m).  · Net profit was €19.9m (€18.1m) and diluted EPS €0.35 (€0.32), negatively impacted by a one-off translation reserve loss on exchange rate of around €3m. The tax rate was further unfavorably impacted by approximately 300 bps from withholding tax on extraordinary large intra group dividends during the quarter. · Cash flow from operating activities was €33.9m (€35.8m).  · During the quarter, Oriflame successfully completed a €70m issue of Euro denominated private placement notes bilaterally agreed with an international investor.  · The year to date sales development is approximately 9% in local currency and the development in the third quarter to date is approximately 10% in local currency. 6 months ended 30 June 2017 · Local currency sales increased by 9% and Euro sales increased by 12% to €687.8m (€615.4m). · EBITDA amounted to €88.3m (€68.3m). · Operating margin was 10.2% (8.4%), positively impacted by 60 bps from currencies, and operating profit was €70.3m (€51.9m).  · Net profit was €39.4m (€28.8m) and diluted EPS €0.69 (€0.51).  · Cash flow from operating activities amounted to €32.5m (€57.3m). CEO Magnus Brännström comments“We are pleased to report double-digit growth in both Euro and local currency with healthy profitability improvements and a strong financial position. During the quarter, our strategic priorities continued to serve as important drivers of growth. CIS experienced local currency growth in the quarter, driven by ongoing productivity increases and positive timing. Asia & Turkey and Latin America were affected by fewer trading days and negative timing of catalogues ­– the underlying performance remained strong. The positive sales momentum for the Group has continued into the third quarter, in which Oriflame celebrates its 50th anniversary Gold Conference.”   OtherA Swedish translation is available on www.oriflame.com. Conference call for the financial communityThe Company will host a conference call on Thursday, 17 August 2017 at 9.30 CET. Participant access numbers:SE: +46856642664DK: +4535445576FIN: +358981710492UK: +442030089808NO: +4723500252US: 18558315947The conference call will also be audio web cast in “listen-only” mode through Oriflame’s website: www.oriflame.com or through http://oriflame-ir.creo.se/170817 August 17, 2017 Magnus BrännströmChief Executive Officer For further information, please contact:Magnus Brännström, Chief Executive Officer Tel: +41 798 263 754Gabriel Bennet, Chief Financial Officer Tel: +41 798 263 769Nathalie Redmo, Sr. Manager IR Tel: +41 799 220 173 This information is information that Oriflame Holding AG is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:15 CET on August 17, 2017. Oriflame Holding AGBleicheplatz 3, CH-8200 Schaffhausen, Switzerlandwww.oriflame.comCompany registration no CHE-134.446.883

Interim report January - June 2017

The group in brief *Adjusted for items affecting comparability, see page 17  For definitions and performance measures, see pages 15 - 18 CEO’s comments Net sales and earnings Net sales for the second quarter increased by 55% to MSEK 36.6 (23.6). The increase was primarily due to higher demand among existing customers, primarily in the snow category, but also promising growth in the motorbike category. The adjusted operating margin was 31.5% (31.2). On a rolling 12-month basis, net sales increased to MSEK 110.4 with an adjusted operating margin of 30.1%. The increase in sales was primarily attributable to existing customers. New solutions of MIPS BPS At the world’s largest cycling trade show, Eurobike, in Friedrichshafen, Germany, in the beginning of September, MIPS will present two new solutions of MIPS Brain Protection System (MIPS BPS). The development of the new solutions was conducted in close cooperation with helmet manufacturers and enables adaptation to several helmet types and models. Both versions are based on the same research and studies as MIPS’ existing patented BPS. Helmets with the new solutions are planned to be in the stores during 2018. More than 40 new helmet models at Eurobike At Eurobike, MIPS’ existing and new customers will present more than 40 new helmet models with MIPS BPS, which will be available in stores in 2018. The models are designed for users in road cycling, MTB (mountain bike), city cycling and downhill cycling. Strengthening the organisation for further growth  During the second quarter, we have strengthened the organisation with competence within strategy and marketing. I am strongly convinced that these people, together with all other employees, will make a positive contribution to further strengthening MIPS’ position. Continued focus on driving knowledge related to rotational motion impact  We are continuing to place major focus on developing new applications, strengthening our market communications and, in collaboration with our customers, continuing to inform and educate the end-users about the damaging effects that rotational motion can have on the brain and how MIPS BPS can help reduce these effects. Johan ThielPresident and CEO For further information, please contact: Johan Thiel, President and CEOjohan.thiel@mipsprotection.comtel +46 73 399 65 88 Max Strandwitz, CFOmax.strandwitz@mipsprotection.comtel +46 70 961 17 54 Boel Sundvall, IRboel.sundvall@mipsprotection.comtel + 46 70 560 60 18 This information is such that MIPS AB (publ) is obliged to disclose in accordance with the EU’s Market Abuse Regulation and the Securities Market Acts. The information was submitted for publication, through the agency of the contact persons set out above, on 17 August 2017 at 7.30 a.m. CET.   MIPS will present the interim report for January - June 2017 at a teleconference on 17 August 2017 at 10.00 a.m. CET. To participate, please register at: http://emea.directeventreg.com/registration/50693432   Financial calendar Interim Report January – September 2017 9 November 2017Year-end report 2017 15 February 2018 About MIPS MIPS is specialised in helmet-based security and protection of the brain and is the world leader in this field.  Based on an ingredient brand model, MIPS Brain Protection System (BPS) is sold to the global helmet industry. The solution, which is patented in all relevant markets, is based on some 20 years of research and development together with the Royal Institute of Technology and Karolinska Institutet in Stockholm, Sweden.MIPS´s headquarter with 24 employees in research and development, sales and administration is in Stockholm, where its test facility is also located. Production takes place at sub-contractor facilities. On a rolling 12-month basis, July 2016-June 2017, MIPS’ net sales amounted to MSEK 110 and an adjusted EBIT-margin to 30%. The MIPS share is since March 2017 listed on Nasdaq Stockholm. For more information, visit www.mipscorp.com Financial targets MIPS’ long-term financial targets should not be viewed as a forecast but rather as an ambition which the Board of Directors and senior executives believe is a reasonable long-term expectation for the company. Growth: The goal is to grow organically to achieve net sales in excess of MSEK 400 by 2020.Profitability: The goal is to achieve an EBIT margin in excess of 40% by 2020.

Acando Interim report January 1-June 30, 2017

Statement by Carl-Magnus Månsson, CEO A continued healthy financial trend with strong growth and rising profits was posted for the first half of the year. Altogether, we grew our sales by 12 percent to SEK 1,234 m and increased profits 35 percent to SEK 130 m. At 10.5 percent, our operating margin is the highest ever for the first six months of the year. In the year’s second quarter, we grew our sales to SEK 613 m, our highest second quarter sales to date, despite the negative effect of fewer working days compared with last year. The positive financial trend is a result of our capacity to develop and thereby remain relevant for customers, partners and employees. Acando’s innovation survey was launched during the quarter, and clearly shows that many larger companies are focusing their innovation capacity on increasing their customer relevance in a world that is rapidly and continuously changing, not least due to all the possibilities opened by digitalization. Acando’s strategy of combining technology, as the driver, together with behavioral insights is thus becoming increasingly relevant. The acquisitions of Transformator Design and Daytona strengthen our capabilities in terms of understanding the customer perspective and securing capacity to design a full omnichannel customer experience, digital and analog. Altogether, this gives us a unique position from which we can not only support definitions of strategies with a strong customer focus, but are also able to realize these through transformative projects ranging from the creation of in-house digital capabilities to the realization of technical solutions. Our compiled expertise makes us unique in the Nordic market. Acando’s strategy of providing customers with a unique possibility for capitalizing on our partner relationships is based on a portfolio of strong, relevant partners and long-standing partner relationships. During the quarter, we expanded our partner portfolio to strengthen our capabilities in the retail/fashion segment and in the cloud-based business systems solution area, both of which are experiencing vigorous growth. More importantly, we were presented with the Partner of the Year award for Sweden by Microsoft for our ability to create innovative and transformative solutions based on Microsoft’s products and services. Moreover, Acando has once again been chosen as an Inner Circle Partner for Microsoft Dynamics, an exclusive global selection of Microsoft’s most strategic partners. Our success relies entirely on our employees’ ambition and capacity to create relations of trust with our customers and their employees. These relationships engender the security to challenge one another and, through shared experiences, abilities and skills, to identify innovative solutions and approaches. We are growing and take pride in the increasing numbers that wish to join us and to continue this quest of creating the most challenging and developing environment for those that have the desire and the courage to match. This report comprises information that Acando AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. This information was submitted through the agency of the above contacts for publication on August 17, 2017 at 08:00 a.m. (CEST).

Wilson Therapeutics to host conference call to provide second quarter 2017 business update

How to participateThe live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q2-2017. Questions can be asked in writing via the webcast or verbally via the conference call. To participate in the conference call, please call one of the following numbers: · SE: +46 8 566 426 90 · UK: +44 203 008 9804 · US: +1 855 753 2235 The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com under Media & Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website. About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information. For further information contact:Anders Martin-Löf, CFO, Wilson Therapeutics ABTelephone: +46 8 796 00 00Email: anders.martin-lof@wtx.se Wilson Therapeutics AB (publ)Corp. Reg. No. 556893-0357Kungsgatan 3SE-111 43 Stockholm

AQ Group AB (publ), interim report January - June, 2017

Second quarter, April- June 2017in brief · Net sales increased by 25% to SEK 1 077 million (860) · Operating profit (EBIT) decreased by 19 % to SEK 74 million (92) · Profit after financial items (EBT) decreased by 22 % to SEK 70 million (91) · Profit margin before tax (EBT %) 6.5% (10.6) · Cash flow from operating activities increased by 3 % to SEK 79 million (76) · Equity ratio 60 % (60) · Earnings per share after tax decreased by 23 % to SEK 3.20 (4.18) Six months, January - June 2017in brief · Net sales increased by 25% to SEK 2 079 million (1 661) · Operating profit (EBIT) decreased by 5 % to SEK 161 million (169) · Profit after financial items (EBT) decreased by 2 % to SEK 163 million (167) · Profit margin before tax (EBT %) 7.8% (10.0) · Cash flow from operating activities decreased by 44 % to SEK 94 million (168) · Earnings per share after tax decreased by 3 % to SEK 7.40 (7.64) A word from the CEO Market The second quarter was our 91st consecutive quarter with profit. AQ’s second quarter with a turnover exceeding a billion SEK. The highest turnover in the history of the group. We have increased our turnover every year since the start October 1, 1994 i.e. for 22 years. We are satisfied with the growth and cash flow is better than in the first quarter 2017, but we are not satisfied with the margin (EBT) 6.5%. We need to work on improving the margin. The organic growth for the quarter was 10.1% compared to 6.2% the second quarter of 2016. The second quarter of 2017 shows our margin sliding downwards, partly because of additional costs in conjunction with increasing utilization and partly because we haven’t succeeded in increasing our prices in the same pace as raw material prices have increased. It is important that we quickly adjust prices to our customers when prices of raw material are increasing. We still have work to do here. We are also intensifying our work to get our supplier base to be more competitive. Our goal is to have an EBT margin of 8%. As we have previously communicated, the second quarter of 2016 had a number of unusually profitable projects in telecom. There is an economic expansion in the industry. Several of AQ’s leading industrial customer show good growth. This partly explains AQ’s high organic growth in the second quarter. In parallel I believe that we are gaining market shares in several business areas. Gradually during the year, several of our production units have had increasing utilization rate and we see a need of increased investments in production capacity in several areas. We have signed an agreement to buy adjacent real estate to our production unit in Hungary. We are negotiating more production space in Poland and we are planning for expansion space in Mexico. This is obviously a good sign that our customers have a good order backlog and that our customers have confidence in AQ. We have had some late deliveries to our customers, which have cost a lot of money in express shipments, overtime and extra personnel. Late deliveries don’t only cost money, the biggest cost is that it affects our customers’ confidence and it’s contrary to our value “We are reliable” and intense improvement work is ongoing. The cash flow from operating activities during the second quarter 2017 was better than the first quarter 2017 and we are working to reduce the capital tied up in accounts receivable and inventory. There is still a pressure from customers to extend credit terms though. Acquisitions Gerdins was acquired on October 3, 2016. It is our biggest acquisition so far when it comes to turnover. The subsidiaries of Gerdins have been integrated into AQ’s existing business areas, the EBT margin is however still below AQ’s goal. We have gained competent and dedicated employees and exciting customers so we are looking positively at the future for “Gerdins” We are always looking at a number of acquisition opportunities. We would like to strengthen our presence and capabilities in the growth areas where we are already present. We also work to follow some of our important customers to completely new geographic regions. Organisation Our focus is always to adapt to customers’ requirements and real demands. It’s a strategy we will continue to follow, to be fast movers and adaptable no matter of market conditions. Our organisation is built on entrepreneurship and it is a foundation of our core values. Outlook My assessment is that we are gaining market shares in several areas and we are also entering new markets. However, one shall be aware of the fact that AQ is acting in a global competition with subsequent price pressure. With operations in 12 countries and more than 5 000 employees it is important for us to maintain our simplicity and speed in our decision making and to minimise bureaucracy which can easily occur in a larger organisation. AQ is well positioned for new acquisitions from a financial as well as from a management view. With strong relations to world leading customers and engaged employees I am looking positively at the future with continued growth with a stable profit level. An important part of this is our core values and our efforts to be a reliable supplier to leading industrial customers. Claes MellgrenCEO

Eltel Group: Interim Report January–June 2017

January–June 2017 · Group net sales amounted to EUR 627.6 million (656.6), down 3.8% in local currencies · Group operative EBITA amounted to EUR -30.7 million (8.9)* · EBIT amounted to EUR -183.0 million (1.7) including a goodwill impairment of EUR 145.6 million · The net result amounted to EUR -185.9 million (-3.7) · Earnings per share were EUR -1.76 (-0.04) · Operative cash flow was EUR -77.1 million (-53.1) April–June 2017 · Group net sales amounted to EUR 329.8 million (369.0), down 9.5% in local currencies · Group operative EBITA amounted to EUR -21.0 million (5.7)* · EBIT amounted to EUR -23.2 million (2.1) including EUR 1.0 million of net items affecting comparability** · The net result amounted to EUR -24.5 million (-0.1) · Earnings per share were EUR -0.23 (-0.00) · Operative cash flow was EUR -10.7 million (-15.7) · Preferential rights issue of EUR 150 million fully subscribed +-------------+------+------+-------++-------------+-------------+-------------+|Business |Jan |Jan |Change,||Apr-Jun 2017 |Apr-Jun 2016 |Change, %*** ||operations  |-Jun |-Jun |%***  || | | || |2017  |2016  | || | | |+-------------+------+------+-------++-------------+-------------+-------------+|Net sales  | | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+|Group  |627.6 |656.6 |-3.8  ||329.8  |369.0  |-9.5  |+-------------+------+------+-------++-------------+-------------+-------------+|Core: Power |222.1 |219.7 |1.0 ||118.3 |124.4 |-4.8 |+-------------+------+------+-------++-------------+-------------+-------------+|Core: |342.3 |332.8 |3.4 ||179.0 |184.8 |-1.3 ||Communication| | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+|Non-core: |63.7 |104.9 |-37.3 ||32.8 |60.2 |-44.4 ||Other | | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+| | | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+|Operative | | | || | | ||EBITA*  | | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+|Group  |-30.7 |8.9  | ||-21.0  |5.7  | |+-------------+------+------+-------++-------------+-------------+-------------+|Core: Power |-0.7 |9.7 | ||-1.2 |7.7 | |+-------------+------+------+-------++-------------+-------------+-------------+|Core: |10.9 |13.3 | ||7.3 |10.3 | ||Communication| | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+|Non-core: |-32.5 |-10.6 | ||-22.5 |-9.6 | ||Other | | | || | | |+-------------+------+------+-------++-------------+-------------+-------------+ Unless otherwise stated, figures in brackets refer to the same period in the preceding year* Items not allocated to segments consist of Group management function including development projects** Items affecting comparability consist of acquisition and sale of business and cost related to reviews and investigations*** Change in local currency Comments by the CEOSuccessful rights issue and transformation focus in a weaker second quarter In June, we successfully completed a preferential rights issue of EUR 150 million. The strong support from our owners has restored the balance sheet to healthy debt levels. This will enable us to continue the execution of Eltel’s new strategy with the goal to focus on our core competences and markets, reduce operational risk, leave non-core markets and increase efficiency. We will further develop our positions in the Group’s core business within Power and Communication in the Nordics, Poland and Germany, which represent approximately 90% of Eltel’s operations. The operations outside Eltel’s core business will be divested or ramped down. The transformation of Eltel is going according to plan. We have merged the power distribution and power transmission units in Power and the mobile and fixed communication units in Communication. During the summer, we divested the unprofitable part of our communication business in Poland and our business operations in Latvia. During the second quarter, net sales declined by approximately 10% to EUR 329.8 million. The decrease is mainly due to the ongoing discontinuation of our unprofitable non-core Power Transmission International business, and our decision to ramp down low-margin sub-station operations within the Power segment. Net sales in our core business – segment Power and Communication – declined by approximately 3% to EUR 297.3 million. The underlying market of our core business continues to be good, although we see temporary lower and delayed investment activity within the power transmission business, which contributed to lower net sales. In segment Communication, volumes both in fibre and mobile in Germany increased, while volumes in the Nordic market declined. Operative EBITA amounted to EUR -21.0 million. The operative EBITA in Eltel’s core business amounted to EUR 6.1 million, but the result in Power was weakened by lower net sales and costs for internal measures to increase efficiency. The non-core businesses accounted for a loss of EUR 22.5 million, including a negative contribution of EUR 18.4 million from Power Transmission International due to the ongoing ramp down of the business. During the first six months of 2017, EUR 26.4 million of the estimated total EUR 40 million of costs and provisions related to the ongoing discontinuation of this business was recorded. The transformation agenda for the remainder of 2017 and 2018 is clear. We will continue the organisational transformation in order to improve efficiencies and adapt the organisation to the new strategy to secure our long-term profitability targets. In addition, we continue our efforts to strengthen internal governance and control. By the end of 2018 we expect to see effects of synergies and growth within our core business areas. Håkan Kirstein, President and CEO For further information:Ingela UlfvesVP – IR and Group CommunicationsTel: +358 40 311 3009, ingela.ulfves@eltelnetworks.com This information is information that Eltel AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 17 August 2017. About EltelEltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2016, Eltel net sales amounted to EUR 1.4 billion. The current number of employees is approximately 8,700. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

Alimak Group: Interim report January – June 2017

·  Solid order intake, revenue and result ·  Continued strong performance in Construction Equipment and After Sales   ·  Integration according to plan and significant contribution on order intake and revenues from acquired businesses Second quarter ·  Order intake increased by 120% to MSEK 1,193 (543) with organic growth of 14% ·  Revenue increased by 128% to MSEK 1,194 (524) with organic growth of 20% ·  EBITA adj. increased to MSEK 173 (92), margin 14.5% (17,6) ·  EBITA increased to MSEK 171 (92), margin 14.3% (17,6) ·  EBIT increased to MSEK 156 (92), margin 13.1% (17.6) ·  Net profit amounted to MSEK 79 (65) ·  Earnings per share amounted to SEK 1.48 (1.38) ·  Operating cash flow amounted to MSEK 44 (67) January-June ·  Order intake increased by 92% to MSEK 2,136 (1,113) with organic growth of 14% ·  Revenue increased by 101% to MSEK 1,971 (980) with organic growth of 14% ·  EBITA adj. increased to MSEK 264 (153), margin 13.4% (15.6) ·  EBITA increased to MSEK 256 (153), margin 13.0% (15.6) ·  EBIT increased to MSEK 235 (152), margin 11.9% (15.5) ·  Net profit amounted to MSEK 129 (94) ·  Earnings per share amounted to SEK 2.57 (2.00) ·  Operating cash flow amounted to MSEK 88 (97) Management assessment, if the during Q1 2017 acquired companies, Avanti Wind Systems and Facade Access Group, would have been fully consolidated by 1 January 2016: order intake growth during the period January-June 2017, would have been 17% and revenue growth would have been 10% compared to the same period 2016 (please find proforma figures on page 17, table 2). Telephone conference / Audiocast A telephone conference / audiocast will be held on Thursday 17 August at 10.00 CET.CEO Tormod Gunleiksrud and CFO Per Ekstedt will present and comment on the report. The presentation, that will be held in English, can also be followed via audiocast. To participate by phone – please call:SE: +46856642666 UK: +442030089804 Link to audiocast: https://tv.streamfabriken.com/alimak-group-q2-2017  For more information, please contact: Per Ekstedt, CFO, telephone: +46 (0)8-402 14 57 Sofia Wretman, Head of Communications and IR, telephone: +46 (0)8–402 14 41 This information in this release is such that Alimak Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 17 August 2017. Alimak Group Alimak Group is a world-leading provider of vertical access solutions for industrial and construction industries. With presence in more than 100 countries, Alimak develops, manufactures, sells and provides service to vertical access solutions with focus on adding customer value through greater safety, higher productivity and improved cost efficiency. The Group´s products and solutions are sold under the brands Alimak Hek, CoxGomyl, Manntech and Avanti. Alimak has an installed base of more than 60,000 elevators, hoists, platforms, service lifts and building maintenance units around the world. Founded in Sweden 1948 Alimak has its headquarters in Stockholm, 12 manufacturing facilities in 8 countries and 2,400 employees around the world. www.alimakgroup.com 

BONESUPPORT HOLDING AB (publ) - Interim Report January - June 2017

Lund, Sweden, 08.00 CEST, 17 August 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT™ platform today publishes its Interim Report, January-June 2017. FINANCIAL HIGHLIGHTS Q2 Net sales increased by 48%  APRIL – JUNE 2017 ·  Net Sales amounted to SEK 37.1 million (25.2), an increase of 48% ·  Gross margin of 87.2% (86.1) ·  Operating loss of SEK -18.4 million (-20.8) ·  Earnings per share, before and after dilution was SEK -0.75 (-0.93) JANUARY – JUNE 2017 ·  Net Sales amounted to SEK 69.6 million (48.4), an increase of 44% ·  Gross margin of 88.0% (85.2) ·  Operating loss of SEK -45.8 million (-34.5) ·  Earnings per share, before and after dilution was SEK -1.82 (-1.62) BUSINESS HIGHLIGHTS APRIL – JUNE 2017 ·  BONESUPPORT HOLDING AB (publ) was listed 21st June at Nasdaq Stockholm and issued new shares raising SEK 500 million gross in conjunction with the IPO ·  BONESUPPORT’s FORTIFY study recruited its first patient ·  At the AGM, it was resolved to amend the Articles of association, change category into a public company and consolidate the shares 5:1 ·  New executive recruitment: Michael Diefenbeck started as Chief Medical Officer SIGNIFICANT EVENTS AFTER PERIOD END ·  The over-allotment option, in relation to the IPO, allowed the Company to raise a further SEK 59 million. The total issue, including the over-allotment option, in conjunction with the IPO, was 19,827,585 shares raising a total of SEK 559 million before transaction costs. Richard Davies, CEO of BONESUPPORT, commented: “BONESUPPORT has made significant progress in recent months. We successfully completed our IPO on Nasdaq Stockholm raising SEK 559 million, before expenses, and in parallel continued to drive the rapid adoption of our CERAMENT bio-ceramic bone substitute products to treat bone voids. We have also enrolled the first patient in the FORTIFY study which is key to potentially gaining approval for CERAMENT G* in the US. Our pipeline of new product candidates designed to enhance bone growth is continuing to making progress as we generate additional pre-clinical data and attract external grant funding. The multiple milestones that we have achieved in the first half of 2017, alongside the strengthening of our management team and the funding from our IPO mean that BONESUPPORT is now well placed to deliver its 2020 financial targets.” The full Q2 Report is available by clicking on the links below: Outside the US: https://www.bonesupport.com/en-eu/financial-reports-inv/   US: https://www.bonesupport.com/en-us/financial-reports-us/  The report will be available on BONESUPPORT’s website from 08:00 am CEST the same day and the presentation from the webcast will be uploaded during the day on the 17th August. Conference Call The Company will host a conference call and an online presentation at 10.00am CEST today. The dial-in numbers for the conference call are: UK: +44 20 30089802 SE: +46 85 6642694 US: +1 855 8315948 Webcast The presentation will also be webcast and can be accessed from the following web address: http://www.financialhearings.com/event/10390 Hosts: Richard Davies, CEO, and Björn Westberg, CFO

Autoliv starts collaboration with Seeing Machines to develop Driver Monitoring Systems

According to the National Highway Traffic Safety Administration, in the United States 3,477 people were killed, and 391,000 were injured, in motor vehicle crashes involving distracted drivers in 2015 alone. The American Automobile Association also states that 21% of crashes in which a person was killed involved a drowsy driver. Autoliv and Seeing Machines have started to collaborate to address this issue by developing a state-of-the-art DMS that can detect distracted and drowsy drivers by accurately measuring eye and head position, driver attention and fatigue. The DMS will invoke action when a dangerous situation is detected or imminent. Reliable understanding of driver state will also enable Autoliv development of technologies critical for supporting highly autonomous driving functions, with safe hands-off-wheel operation. Within the collaboration, Autoliv will serve as the Tier 1 supplier to automotive OEMs to produce the driver monitoring systems for future awarded business. "Autoliv and Seeing Machines have teamed up to reduce distracted driver accidents," says Johan Löfvenholm, President, Autoliv Electronics. "We both share a passion for saving more lives, and together, we will create one of the most advanced driver monitoring systems in the world." “The collaboration between Seeing Machines and Autoliv is an excellent fit within our expanding partnership ecosystem” added Mike McAuliffe, CEO of Seeing Machines. “Both companies are technical leaders deeply committed to advancing safer driving through the development and deployment of our advanced DMS technologies for Automotive OEMs”. Inquiries: Thomas Jönsson, Vice President Corporate Communications. Tel: +46 8 587 206 27 About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 80 facilities with 70,000 employees in 27 countries. In addition, the Company has 22 technical centers in ten countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2016 amounted to about US $10.1 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at www.autoliv.com. About Seeing Machines Seeing Machines, (AIM: SEE) is an industry leader in computer vision based technologies which enable machines to see, understand and assist people. With more than 17 years of deep domain experience, Seeing Machines deploys its proprietary computer vision platform to deliver precision tracking and analysis of heads, faces and eyes. A primary application is Automotive Driver Monitoring Systems (DMS) to detect and help deal with drowsiness, distraction and other cognitive states which is key to the adoption of ADAS and Autonomous Driving as well as our pioneering Guardian Fleet safety product. Seeing Machines' technology has been adopted by global industry leaders across the market spectrum. Seeing Machines is headquartered in Canberra, Australia and currently has offices and people in Melbourne, Tucson, Silicon Valley, Detroit and the UK. For more information visit www.seeingmachines.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements, including statements regarding the ability of the parties to successfully collaborate, develop and commercialize driver monitoring system technologies, are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update any such statement, except as required by law.

Interim Report period from January 2017 to June 2017

       IMPORTANT EVENTS DURING THE PERIOD · On March 10th, the Company announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment of vaginal atrophy, were not met. However, further analyses of the study data showed that the gel, both without and with the active ingredient (oxytocin), had a marked and statistically significant alleviating effect on the Most Bothersome Symptoms (MBS) after the twelve week treatment. To enter a clinical phase 3 programme, a new phase 2b study would be required. Hence, the Company has decided to focus on bringing the oxytocin-free gel to the market as a non-prescription product. · On May 17th, the Company announced that the results of the exploratory part of its clinical phase 2b study show comparable treatment effects to the first part (main study). In short, this means that no significant differences were found between placebo and oxytocin for any of the defined clinical endpoints, whereas the placebo gel gave a strong effect on the Most Bothersome Symptom (MBS). All study subjects of the placebo arm (10 out of 10) reported symptom relief and half of them were symptom free at the end of the treatment period. · At the AGM on the 18th of Mayt Leni Ekendahl and Marianne Östlund were elected as new board members. Arne Ferstad and Hans von Celsing were re-elected, Hans von Celsing as chairman. · InJune the Company closed a financing round of 13.4 MSEK (before issue costs) consisting of a preferential rights issue (12.3 MSEK) and a private placement (1.1 MSEK).As a result, the number of shares will increase from 20.6 million to 43.0 million. · On May 30th the Company announced that it has filed a patent application concerning the use of its vaginal gel for the treatment of symptoms associated with vaginal atrophy. The application was filed with The Swedish Patent and Registration Office. During the coming twelve months, the Company will decide in which additional countries the application will be filed. IMPORTANT EVENTS AFTER THE END OF THE PERIOD · On 1st of August the new shares issued in the latest financing will be transformed from BTA to ordinary shares. · On 14th of August the Swedish “Bolagsverket” informed the Company that the last lot of issued shares (1,808,332 shares) have been registered.  From the CEO During the second quarter much of the activities in Peptionic focused on defining and describing the new strategy of the Company, which is to launch VagiVital™ as a non-prescription product for the treatment of vaginal dryness/atrophy. VagiVital™ is the placebo gel that gave such a good effect in the treatment of the symptoms associated with vaginal atrophy in the most recent clinical study. The magnitude of the effect was on par with those reported from clinical studies with estrogens and estrogen-like products. This was both surprising and encouraging. Before we can launch VagiVital™ it has to be CE-marked. This, in turn, requires a quality system to be implemented in the Company (according to ISO 13485) and a so called Technical File to be produced and approved. The approval is issued by a so called Notified Body, which is our case is Lloyds Register Quality Assurance Ltd. (England). To realise our plans, additional capital is required. Hence, we closed a rights issue with preferential rights and a private placement in May-June. The gross proceeds of these two fund raisings were 13.4 MSEK and issue costs amounted to 2.5 MSEK. The rights issue with preferential rights was over-subscribed by 18 per cent, which indicates a positive attitude by the market towards the new strategy of the Company. This is encouraging and gives us energy and motivation to go forward towards a product launch. The proceeds are expected to cover the costs of obtaining the CE mark and for preparing and planning the first launch. In addition to investing time and resources on obtaining the CE mark, we will work diligently to develop winning strategies for the distribution and marketing of VagiVital™. Outside the Nordic countries we will look for partners. On our home market (Sweden/Nordic countries), we are evaluating different alternatives, but also here we may want to collaborate with well established companies in this product category. The interest for VagiVital™ among potential partners is at least as high as the interest for our previous candidate product containing oxytocin. VagiVital™ is a medical device product that requires a less complicated and less costly registration process than a drug. Also, VagiVital™ can reach the market much sooner (several years) than our previous candidate drug. Discussions with potential partners are well underway. In Peptonic, we have an exciting and work intensive autumn ahead of us. We will of course keep the market informed about how the work is progressing. Johan Inborr CEO Stockholm, August 17th, 2017 COMPANY BRIEF  Peptonic Medical AB (publ) is an innovative Swedish biopharma company developing products within the field of women’s health. The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free product for the treatment of vaginal atrophy. VagiVital® is a registered trademark of Peptonic Medical. The product is being developed for the non-prescription use for the treatment of vaginal atrophy. Find out more at www.peptonicmedical.se FINANCIAL INFORMATIONNet sales – Currently the company has no sales. Costs – Costs for the second quarter were KSEK -2,559 (-2,770). Costs for the first half year were KSEK -5,240 (-6,321). Result – Loss before taxes for the second quarter was KSEK -2,592 (-2,775). Loss before taxes for the first half year was KSEK -5,273 (-6,312).Financial position and liquidity – Liquid assets were KSEK 3,333 (16,477) as of June 30, 2017. After finished funding in July 2017 has the company increased the liquidity with 11.0 MSEK after costs. Equity – The equity amounted to KSEK 56,369 (61,189) as of June 30, 2017. 90 (92) percent of which is shareholders funds.Organization – The average number of employees during the period was 2 (2). At the end of the period the number of employees was 2 (2). Share – Total numbers of shares in the company amounted to 20,602,984 (19,174,412), as of June 30, 2017. After on-going funding it will increased to a total of 43,014,300 shares.

Cherry adjusts full-year forecast

Cherry AB (publ) shows continued strong development in all business areas with profitable growth. In December 2016, in connection with Cherry calling the option to acquire the remaining 51% of the shares in ComeOn Malta Ltd, the Group provided a forecast. The Cherry Group, together with acquired ComeOn, was estimated to generate total revenue for the full year 2017 of between SEK 2,600 and SEK 2,700 million, with an EBITDA of SEK 550 to SEK 600 million. The rapid merging of the online gaming operations to ComeOn! has resulted in intensive integration work and thus affected growth. Given that the merger has not yet reached a full positive effect on the Group's revenue and earnings, Cherry adjusts its forecast for the full year 2017. The Company now expects the Group to generate total revenue of approximately SEK 2,500 million in 2017 and EBITDA is expected to amount to approximately SEK 480 million. Cherry publishes its interim report for the second quarter on 24 August, 2017. For further information, please contact: Anders Holmgren, VD, +46 708 607 534, anders.holmgren@cherry.seChristine Rankin, CFO +46 765 399 492, christine.rankin@cherry.seCarolina Haglund Strömlid, Head of IR & Communications, +46 708 807 173, carolina.stromlid@cherry.se This information is information that Cherry AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on 17 August 2017. CHERRY IN BRIEF Cherry is a Swedish innovating and fast growing gaming company established in 1963. The business strategy is to create shareholder value by owning and developing fast-growing and profitable businesses within the gaming and casino industry. Cherry operates within five diversified business areas, Online Gaming through ComeOn!, Performance-based Marketing through Game Lounge, Gaming Technology through XCaliber. Game Development through Yggdrasil Gaming and Highlight Games and Restaurant Casino through Cherry Spelglädje. The objective is to grow organic in combination with strategic acquisitions of fast-growing companies. Cherry employs around 1 100 people and has more than 6,000 shareholders. The Company’s B-shares are listed on AktieTorget.

NeuroVive Pharmaceutical AB Interim report January - June 2017

Business operations Significant events April-June 2017 · The anti-fibrotic effects of NV556 in non-alcoholic steatohepatitis (NASH) was confirmed in an additional experimental model. The preclinical data was presented at The International Liver Congress™ in Amsterdam.  · At the Annual General Meeting on 27 April, two new board members were elected: Jan Törnell, adjunct Professor at the Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, and David Bejker, CEO of Affibody Medical AB  · NeuroVive entered into a global licensing agreement on Yungjin Pharm’s compound KL1333 for genetic mitochondrial disorders. The clinical phase I study of KL1333 was initiated in South Korea end of June. · In May, NeuroVive announced positive results from clinical and preclinical studies with its drug NeuroSTAT® for the prevention of the sequelae of traumatic brain injury (TBI). The results have enabled NeuroVive to proceed into the next stage of clinical development amd the company has therefore decided to close the clinical phase IIa study CHIC in advance and focus all TBI project efforts on preparing for the next clinical study with NeuroSTAT for TBI. Further analyses and additional data were presented at the Annual National Neurotrauma Symposium, Neurotrauma 2017, in Snowbird, Utah, on 9-12 July, by Michael Karlsson.  · NeuroVive received close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseases. Johannes Ehinger presented the project at UMDF’s (United Mitochondrial Disease Foundation) meeting in Washington DC end of June.  Important events after the end of the period · NeuroVive signed a private placement agreement with Esousa Holdings LLC, a New York-based family office investing in emerging growth companies, which will raise gross proceeds of 9 million SEK divided in two equal tranches. The first tranche was completed on 18 July.   Financial information Second quarter (April-June 2017) · Net revenues were SEK 0 (0) and other operating income was SEK 88,000 (28,000) · Loss before tax was SEK 22,256,000 (loss: 12,059,000) · Earnings per share* was SEK -0.45 (- 0.34) · Diluted earnings per share** amounted to SEK -0.45 (- 0.34) First six months (January-June 2017) · Net revenues were SEK 27,000 (0) and other operating income was SEK 152,000 (74,000) · Loss before tax was SEK 43,646,000 (22,975,000) · Earnings per share* were SEK -0.79 (-0.64) · Diluted earnings per share** were SEK -0.79 (-0.64) *                 Profit/loss for the period divided by average number of shares before dilution at the end of the period. **               Profit/loss for the period divided by average number of shares after dilution at the end of the period Please find the complete interim report attached below. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on 17 August 2017.

Results from extension study with C21 show safety, tolerability and indicate effects on lipid metabolism

The extension study, initiated in January 2017, was performed on a group of overweight men (BMI 30-35) and with a hip to waist ratio below 0.9 but otherwise healthy. In total 16 volunteers, whereof 8 were given 100 mg C21 and 8 were given placebo during a period of 8 days participated. The aim of the study was to evaluate safety and tolerability of C21 in a group with a potentially compromised metabolic situation and to investigate if markers of metabolic dysfunction could be affected by C21 during the short treatment period.  The results from the study verified that C21 is well tolerated and safe also in this group as there were no serious adverse effects noted or adverse readings from the laboratory analyses for a large number of biomarkers. In addition, the group receiving C21 demonstrated a tendency to lowering of plasma LDL (low density lipoprotein), the harmful form of cholesterol. Further detailed analysis are still ongoing.  “In view of the small size of the study one should be careful to draw far-reaching conclusions but it is encouraging that we with the support of the study results can formulate a hypothesis that C21 can have positive effects on lipid metabolism” says Professor Mika Scheinin, Principle Investigator for the study, University of Turku, Finland.  The outcome adds to the safety profile of C21 and is important for upcoming Phase IIa study where C21 will be tested on patients suffering from Idiopathic pulmonary fibrosis (IPF).   For further information, please contactPer Jansson, CEOM: +46 709 17 47 46 or e-mail: per.jansson@vicorepharma.com  This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication August 17, 2017 at. 08:50 CET.

Ericsson sues Wiko for patent infringement

On August 14, 2017, Ericsson (NASDAQ: ERIC) sued smartphone maker Wiko, in the regional courts of Düsseldorf and Mannheim in Germany, for infringement of patents essential for 2G, 3G and 4G cellular technology, as well as implementation patents. Wiko has been infringing Ericsson’s intellectual property rights for six years without any license or compensation. Ericsson has tried to establish a fair, reasonable, and non-discriminatory (FRAND ) license agreement with Wiko since May 2013, but has not succeeded. As a last resort, Ericsson has decided to exercise its legal rights to enforce its patents against Wiko’s infringing products. Gustav Brismark, Chief Intellectual Property Officer at Ericsson, says: “Global sharing of technology and open standards are the force behind the smartphone revolution and have allowed new entrants, such as Wiko, to quickly build successful businesses. This ICT eco-system only works, however, if all market players respect the basic rules of FRAND licensing. It is unfair for Wiko to benefit from our substantial R&D investment without paying a reasonable license fee for our patented technology. "Our ambition has always been to reach a mutually fair and reasonable license agreement with Wiko, just as we do with all of our licensees.” Ericsson has one of the industry’s strongest intellectual property portfolios, which includes more than 42,000 granted patents worldwide. Ericsson’s patent portfolio covers 2G, 3G and 4G/LTE technologies, and the company plays a key role in the global organizations that are developing standards for 5G technologies. NOTES TO EDITORS Ericsson IPR press kit   Ericsson on FRAND and standards   More information about Ericsson IPR & Licensing   For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson  MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790

The Phase 1b study regarding IRL790, which was concluded during spring 2017, provided positive and very valuable information about safety, tolerability, dosing and efficacy, supporting the planning of the upcoming Phase 2 study. This study aims to confirm efficacy indicated in the phase Ib study and further examine safety and tolerability of IRL790 in the treatment of Parkinson’s disease patients suffering from L-dopa Induced Dyskinesias (PD-LIDs), an indication with limited treatment options and big medical need. An agreement has been signed with TCTC, a Clinical Research Organisation (CRO), to conduct the study. Together with TCTC, IRLAB now has the organisation in place to conduct the Phase 2 study in the UK. “The results from Phase 1 and Phase 1b studies in patients with Parkinson’s disease and levodopa-induced dyskinesia in Sweden is promising for the continued development of IRL790. We have recently completed a feasibility analysis in the UK and found that UK clinics have a high clinical competence regarding Parkinson’s disease, a large patient base, and interest in conducting the Phase 2 study. We are looking forward to working with our colleagues at TCTC who have an extensive experience from conducting international clinical trials in neurodegenerative diseases”, says Joakim Tedroff, IRLAB’s chief medical officer (CMO). “TCTC is delighted to work with IRLAB on this study. There is a huge unmet medical need to improve the lives of patients with Parkinson’s disease and IRL790 is an exciting new potential treatment for patients with Parkinson’s disease dyskinesia.  We are very much looking forward to working with the IRLAB team and the UK investigators to deliver this important study”, says Susan McGoldrick TCTC’s CNS Project Director. About IRL790 IRL790 is developed for the treatment of PD-LIDs, involuntary movements that often follows treatment with levodopa, and PD-P, psychosis in Parkinson’s disease. In pre-clinical studies, IRL790 reduces involuntary movements that occurs after a period of treatment with L-dopa. Additionally, in pre-clinical studies, IRL790 has shown antipsychotic properties. The company believes that IRL790 thus has the potential to simultaneously treat both dyskinesias and psychosis in Parkinson’s disease.

Trelleborg invests in high-end production for sealing solutions in Denmark

Trelleborg has, through its business area Trelleborg Sealing Solutions, decided to invest in a new state of the art production facility for sealing solutions in Denmark, thus relocating its current manufacturing facility in the country. The move is intended to transform and further expand the current capabilities of the existing facility to demonstrate future manufacturing principles and technologies that enable profitable sales growth. The investment forms part of Trelleborg’s strategy to strengthen positions in attractive market segments. “The Danish operation is one of our most important ones globally, with committed employees and a product and material portfolio that offers high-end solutions to the most demanding of sealing applications. The new production facility will be dedicated to highly automated and lean production lines for the automotive, aerospace and renewable energy industries, contributing to better business and higher technical customer support,” says Claus Barsøe, President of the Trelleborg Sealing Solutions business area. The production will be relocated to a new facility close to the current one in Helsingør, Denmark. Trelleborg will invest a total of approximately SEK 120 M during 2017-2020. The investment for this year is within the previously announced framework for capital expenditures for 2017. It is estimated that production will be able to commence in the new facility at the beginning of 2020.

Holmen’s interim report January–June 2017

Quarter  January–June Full Year     SEKm  2-17  1-17  2-16  2017 2016 2016 Net sales  4 148 4 131  3 937 8 278 7 765 15 513 Operating profit 525 627  483 1 152 1 063 2 162 excl.items affectingcomparability Operating   525 627  483 1 152 831 1 930 profit Profit after   394 485  364 880 587 1 424 tax Earnings per   4.7 5.8  4.3 10.5 7.0 16.9 share, SEK Operating   12.7 15.2  12.3 13.9 13.7 13.9 margin, % * Return on   8.5 10.2  7.7 9.4 8.4 8.6 capital employed,% * Return on   7.5 9.2  7.1 8.4 5.7 6.9 equity, % Cash flow   482 742  478 1 224 1 232 2 320 beforeinvestmentsand workingcapital Debt/equity   0.19 0.16  0.22 0.19 0.22 0.19 ratio  *Excluding items affecting comparability of SEK -232 million in 2016. See also page 15. · Operating profit for January–June 2017 was SEK 1 152 million (January–June 2016: SEK 1 063 million, excluding items affecting comparability). The improvement in earnings was due to higher wood product prices, better earnings from forests and the divestiture of the newsprint mill in Madrid. · Compared with the first quarter, operating profit decreased by SEK 102 million to SEK 525 million as a result of a maintenance shutdown within paperboard and seasonally lower hydro power production. · Profit after tax for January–June amounted to SEK 880 million (587), which corresponds to earnings per share of SEK 10.5 (7.0).  ·  Return on capital employed increased to 9.4 (8.4) per cent. · Production of paperboard, paper and wood products has been established at a higher level than previous years and the sales mix has developed well. Cash flow was strong and largely covered the SEK 1 billion dividend that was paid in April. For further information please contact: Henrik Sjölund, President and CEO, tel. +46 8 666 21 05 Anders Jernhall, EVP and CFO, tel.  +46 8 666 21 22Stina Sandell, Director of Sustainability and Communications, tel +46 739 86 51 12 This information is information that Holmen AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 17 August 2017 at 12.45 CET.

Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527

Seattle, WA, and Lund, Sweden – August 17, 2017 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the companies have initiated CMC activities for the manufacturing of clinical material in preparation for a future investigational new drug (IND) submission for the bispecific immuno-oncology antibody ALG.APV-527. ALG.APV-527 was the subject of a collaboration agreement announced by the companies in July 2017 . It targets the co-stimulatory receptor 4-1BB and an undisclosed tumor antigen that directs the immune activation to the tumor area. 4-1BB is known to enhance the immune response to cancer through activation of tumor-specific T cells and is believed to be a promising target for new immunotherapeutic approaches. The bispecific antibody candidate could potentially have utility in the treatment of a broad spectrum of cancers over-expressing the tumor antigen, including breast, cervical, non-small-cell-lung, prostate, renal, gastric, colorectal and bladder cancers. “With CMC and IND enabling activities underway, our partnership with Aptevo is moving ahead rapidly”, said Per Norlén, Chief Executive Officer of Alligator Bioscience. “Having worked collaboratively to design and engineer ALG.APV-527, we are pleased to now announce its advancement into preclinical development. This bispecific antibody brings tumor directed immunotherapy to the next level. By making the immune activation dependent on binding to a tumor antigen we have created a candidate drug with potential for improved efficacy and fewer side effects.” “The timely progress we are making underscores our respective companies’ expertise in bispecific antibody engineering and we are very excited to begin the next phase of development of ALG.APV-527 and further demonstrate the elegance of our ADAPTIR technology platform”, said Marvin L. White, President and Chief Executive Officer of Aptevo.  “The robust and flexible nature of our ADAPTIR platform permits the development of bispecific antibodies with different mechanisms of immune system engagement.  Because ADAPTIR bispecifics are based on an IgG backbone, they have excellent stability and manufacturing characteristics, with traditional monoclonal antibody-like manufacturing properties – a key differentiator from other bispecific constructs.  As an emerging class of new therapeutics, bispecific antibodies may offer important technological advancements over traditional monoclonal antibodies, including the potential for more precise targeted therapy through enhanced functionality, potency and efficacy.  We look forward to advancing ALG.APV-527 towards IND submission and to further validating the utility of our ADAPTIR protein therapeutic platform.” For further information:Alligator BioscienceCecilia Hofvander, Director Investor Relations & CommunicationsE-mail: cecilia.hofvander@alligatorbioscience.com Aptevo TherapeuticsStacey Jurchison, Sr. Director, Investor Relations and Corporate CommunicationsPhone: +1 206-859-6628E-mail: JurchisonS@apvo.com This information is information that Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 01:00 p.m. CET on 17 August 2017. About Aptevo Therapeutics Inc.Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives.  The Company has four commercial products – IXINITY®, WinRho®, HepaGam B®and VARIZIG®and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated, bispecific antibodies with unique mechanisms of action.  Aptevo’s primary focus is immuno-oncology, with two ADAPTIR candidates currently in clinical development and a broad portfolio of bispecific immunotherapies in preclinical development.  For more information, please visit www.aptevotherapeutics.com. About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical product candidates (ADC-1013, ATOR-1015, ATOR-1017, and ALG.APV-527) and novel research candidates. ADC-1013 is licensed to Janssen Biotech, Inc., part of J&J, for development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit www.alligatorbioscience.com . Safe Harbor StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo’s outlook, financial performance or financial condition, our technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, Aptevo’s future growth rates, Aptevo’s ability to timely manufacture its products, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; the ability of our contractors and suppliers to supply product and materials;  our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets and our ability to retain patients; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Annual Report on Form 10-K, as filed on March 15, 2017, and our subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.

Voting results from Haldex’ Extraordinary General Meeting

Haldex held an Extraordinary General Meeting on August 17 in Stockholm, Sweden. Haldex has earlier today announced that the EGM resolved to approve the proposal by Knorr-Bremse, 54% of the shareholders were present at the EGM which represents 23,888,027 of the votes. Of these 15,489,074 refrained from voting, including ZF, 403,096 voted against the proposal and 7,995,857 voted for the proposal. "Let’s not exaggerate any disappointment that we now feel in the Board of Directors. Owners sometimes think and vote differently than the Board ant that is entirely in accordance with the rules of the game. Today's action by ZF is disappointing for Haldex because our main owner chooses to refrain from clarifying its interests and a minority of the shareholders, mainly short-term speculative owners, puts Haldex in a continued uncertain situation.", says Jörgen Durban, Chairman of the Haldex Board. As no new information was presented about Knorr-Bremse’s plans to address the antitrust issues, despite the fact that Knorr-Bremse's CEO Klaus Deller gave a speech, the Board continues to assess the likelihood of getting the deal approved as very low. The Board therefore adhere to its earlier decision not to support Knorr-Bremse’s bid as it would result in material harm for the company and contravene the Companies Act. The Board is to protect the interests of all shareholders. In this case, a few owners have voted on a proposal that benefits a minority of shareholders while it destroys long-term shareholder value.

Prominent Italian Tomato Grower Gandini Antonio S.S. Selects Heliospectra LED Lighting Solutions

The order includes Heliospectra’s new E50 series lighting solution. A 500 Watt, durable industrial standard high voltage LED lighting solution, developed to complement Heliospectra’s commercial product portfolio. The E50 series significantly reduces energy and utility costs when compared to traditional high pressure sodium (HPS) lights often used in controlled environment agriculture. “We are now starting to reap the rewards of our increased focus working with commercial producers in the food industry, as well as building strong partnerships with well-known local resellers. By introducing the high-voltage E50 solution we are able to serve a segment we haven’t been able to serve so far. Commercial growers, like Gandini Antonio, recognize the value and business advantages of upgrading to LED technology,” said Ali Ahmadian, CEO of Heliospectra.   The installation will be the first installation of the E50 series in Europe. Delivery will take place during the beginning of Q4 and be visible in the accounts in Q3 and Q4.  About Ageon S.r.l. Ageon is a society located in Cuneo (Piemonte, Italy). Since its foundation, in 1993, Ageon has been involved in the Covered Agriculture Market. Its' vision is to be a “solution provider” for its' Customer, in order to establish a strong partnership and get the best possible results from production. Ageon offers a wide range of products and an affective consultancy service for cultivation in controlled environments. For more information please visit www.ageon.it  - 0039 (0)171 348114 Join the Heliospectra conversation:  ●      Read more at www.heliospectra.com/blog  ●      Follow @Heliospectra  on Twitter ●      Like Heliospectra on Facebook at facebook.com/heliospectra 

Q2 2017 Interim report January−June

August 18 2017 Second quarter of 2017 · Revenues totalled EUR 15.10 million (9.58), an increase of 58 percent year-on-year (YoY). · Operating profit increased to EUR 5.38 million (5.07) corresponding to an operating margin of 36 percent (53). Adjusted operating profit excluding costs related to the new bond issue and the preparation for the planned change of listing to NASDAQ Stockholm, amounted to EUR 7.06 million (5.01), corresponding to an adjusted operating profit margin of 47 percent (52). · EBITDA amounted to EUR 6.27 million (5.32) corresponding to an EBITDA margin of 42 percent (56). Adjusted EBITDA excluding costs related to the new bond issue and preparation for the planned change of listing to NASDAQ Stockholm, amounted to EUR 7.95 million (5.26), corresponding to an adjusted EBITDA margin of 53 percent (55). · Earnings per share amounted to EUR 0.102 (0.089) before dilution. · Earnings per share amounted to EUR 0.100 (0.089) after dilution. · Search revenue at all time high EUR 11.53 million (7.27), an increase of 59 percent YoY corresponding to 76 percent of total revenues. · Record in new depositing customers (NDCs) which totalled 91,222 (47,530), an increase of 92 percent YoY and an increase of 13 percent compared to the previous quarter. First six months of 2017 · Revenues totalled EUR 30.33 million (17.04), an increase of 78 percent YoY. · Operating profit increased to EUR 12.03 million (8.25) corresponding to an operating margin of 40 percent (48). Adjusted operating profit excluding non-recurring expenses, which during this period comprised costs related to the new bond issue and the preparation for the planned change of listing to NASDAQ Stockholm, amounted to EUR 14.05 million (9.17), corresponding to an adjusted operating profit margin of 46 percent (54). · EBITDA increased to EUR 13.49 million (8.66) corresponding to an EBITDA margin of 44 percent (51). Adjusted EBITDA excluding costs related to the new bond issue and preparation for the planned change of listing to NASDAQ Stockholm, amounted to EUR 15.51 million (9.58), corresponding to an adjusted EBITDA margin of 51 percent (56). · Earnings per share amounted to EUR 0.186 (0.164) before dilution. · Earnings per share amounted to EUR 0.182 (0.163) after dilution. · NDCs totalled 171,643 (79,851), an increase of 115 percent YoY. Q2 comments from Robert Andersson, CEO A successful quarter with strong underlying developments Catena Media continued its strong development in the second quarter of 2017. Through our scalable business model, we managed to gain revenues that amounted to EUR 15.10 million, corresponding to a year-on-year revenue-growth of 58 percent. Furthermore, adjusted EBITDA was at an all-time-high of EUR 7.95 million, corresponding to an adjusted EBITDA margin of 53 percent. We referred 91,222 NDCs to our clients in the second quarter, an increase of 92 percent year-on-year and an increase of 13 percent compared to the first quarter. The strong development of this key performance indicator is a reflection that the underlying business development continues to be strong and healthy. Search revenues are at an all-time-high of EUR 11.53 million, an increase of 58 percent year-on-year, and an increase of 5 percent compared to the previous quarter despite a negative impact of EUR 0.3 million as a result of withdrawing from the Dutch market. Paid revenues amounted to EUR 3.11 million, an increase of 35 percent year-on-year but a decrease of 16% compared to the previous quarter due to sports seasonality and the ongoing shift to perpetual revenue models on paid media. Speeding up product innovation The second quarter has been characterized by the highest rate of product launches ever. The announcement and debut of the revamped JohnSlots website, one of Catena´s most important brands, has been a success with a significant increase in traffic. We are also proud to have launched our first e-sports site, called gamerbetz.com, which is a partnership with Gamerz, a global e-sports reality TV show.  In addition to this, we launched a new sports podcast in Sweden which quickly became a success.  Seasonal effects Historically, seasonal effects on revenues have been quite limited since online casino behaviour is typically less sensitive to seasonality. However, since an increasing portion our revenues are now generated from Sports, we will naturally start to experience more seasonal effects. Sports turnover is closely correlated with available sports events at any given time, and this summer is particularly slow due to lack of any big sports events.  Catena temporarily withdraws from the Dutch market Catena Media adheres to strict compliance standards regarding the operators to whom it supplies traffic through its affiliate network and operates in compliance with applicable laws. Recently, the Dutch Gaming Authority, KSA, decided to take a stricter approach to iGaming sites that target Dutch players, and as a result Catena Media decided to temporarily withdraw from the Dutch market to fully comply with applicable law.  Short term this will impact revenues negatively by approximately EUR 100-150 thousand per month, but longer term it puts us in a favorable position, if and when, the Dutch market re-regulates. The Upper House of Parliament is currently considering the Remote Gaming bill which aims to regulate online gambling.  Office expansion As a result of our fast paced growth, we have outgrown our office spaces in London, Malta and Serbia. Therefore, we have moved into brand new offices in both London and Serbia during the first quarter and we are now in the process of moving into our brand new headquarters in Malta. The office expansion enables us to continue building our already strong and multifaceted workforce, currently consisting of 239 engaged employees from over 30 countries. Strategic update Through both organic and acquired growth, Catena Media´s vision is to become the world´s number one provider of high-value iGaming leads. During the second quarter, Catena Media acquired three affiliate networks, including affiliate websites, accounts and associated agreements. In July, we acquired the award–winning sports affiliate Bettingpro.com and related affiliate assets. These acquisitions further cement our role as the leading consolidator in the affiliate market. In June, we were successful in raising EUR 50 million, the second tranche of our EUR 100 million bond. The proceeds will primarily be used for further acquisitions, and we are in ongoing talks with several potential targets. Our strategic decision to focus more on perpetual revenue has continued, and 64 percent of the revenues in the second quarter was generated from perpetual revenue share agreements, up from 51 percent in the first quarter. This has negative short-term effects on revenues and margins, particularly in paid media where upfront payments are typically higher, but longer term it is believed to generate more revenue per customer. As from the fourth quarter and onwards we expect to start seeing the benefits from this strategic shift in a more noticeable way. Regulated and near-regulated markets continues to be a core focus area for Catena Media, and it is estimated that approximately 60 percent of the revenue stems from licensed operators in regulated markets. If we include Sweden, which is likely to be regulated in the not too distant future, the regulated share would increase to over 70 percent. This shows that Catena Media is well prepared to face the ongoing regulatory changes happening across Europe at the moment. Also, our planned listing on NASDAQ Stockholm (Mid Cap) is progressing well and the aim is to complete this change of listing during the second half of 2017. Outlook With strong underlying developments and the sports season starting full throttle mid-August, the table is set for a very exciting second half of the year. We remain optimistic on our strategic, operational and financial development, and are confident that the we will continue to grow in the same successful way, both through organic growth and through acquisitions across existing and new geographic markets. For further information, please contact: Robert Andersson, CEOPhone: +356 770 329 28,E-mail: robert.andersson@catenamedia.comwww.catenamedia.com Anne Rhenman, Investor Relations Phone: +356 9936 8218E-mail: anne.rhenman@catenamedia.comwww.catenamedia.com This information is information that Catena Media plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 18, 2017 at 07.00 CET. About Catena Media Catena Media is a fast-growing online performance marketing company, having established a leading position through strong organic growth and acquisitions. The company was founded in 2012 and has 239 employees in the US, Serbia, UK and Malta, where the Head Office is situated. The company is listed on Nasdaq Stockholm First North Premier. In 2016, revenues reached EUR 40 million. The Certified Advisor is Avanza.

BerGenBio ASA: Results for the Second Quarter and Half year 2017

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “During the first half of 2017, BerGenBio has undergone substantial development and made important progress: the Company has completed a successful IPO; signed a clinical collaboration agreement with Merck & Co (MSD); and initiated a programme of Phase 2 clinical trials, which aim to demonstrate the clinical potential of BGB324, a first-in-class, selective, Axl inhibitor as a new treatment option for patients with difficult-to-treat cancers. Axl inhibition has the potential to prevent and reverse an essential survival mechanism that tumour cells employ to evade immune detection, resist therapy and spread (metastasise) to other parts of the body. BerGenBio’s leadership in Axl inhibition ideally positions the Company to address the major unmet medical need resulting from this common resistance mechanism. The Company has a clear strategy to develop BGB324 and other Axl inhibitors, and the funds from the recent IPO will enable BerGenBio to complete the four ongoing Phase II trials, with read-outs expected in the second half of 2018 representing important points of validation.” Operational Highlights · IPO completed, raising NOK 400 million from new and existing investors to fund further clinical development of BGB324 and pipeline programmes · BerGenBio shares began trading on OSE on 7 April 2017 under the ticker BGBIO · Clinical collaboration agreement signed with Merck & Co (MSD) to evaluate combination of BGB324 with KEYTRUDA® (pembrolizumab) · BGB324 – four Phase II clinical trials ongoing · Following compelling Phase Ib data reported December 2016, recruitment continues with BGB324 as a single agent therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS) · Following compelling Phase Ib data reported in November 2016, Phase II clinical trial continues with BGB324 plus TARCEVA® (erlotinib) in advanced EGFR-positive lung cancer patients · Sites active and patient recruitment ongoing for combination study of BGB324 plus KEYTRUDA in triple negative breast cancer patients · Protocol accepted and site activation underway for combination study of BGB324 plus KEYTRUDA in advanced lung cancer patients · Two Phase II investigator-sponsored studies initiated · First patients dosed in Phase Ib/II trial of BGB324 in combination with docetaxel in advanced lung cancer · First patients dosed in randomised Phase II trial of BGB324 in combination with targeted therapy or KEYTRUDA in advanced melanoma · Clinical and scientific presentations at global cancer conferences · Phase II melanoma study design and preclinical evidence supporting BGB324’s potential to re-sensitise lung and breast tumours to checkpoint inhibitors presented at American Association for Cancer Research (AACR) Annual Meeting in April · Anti-tumour activity of BGB324 demonstrated in vitro and in patients with high-risk MDS presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in May · Non-dilutive grants to support clinical trials of BGB324 · NOK 24 million IFU grant from Innovasjon Norge · Awarded a grant from the Research Council of Norway under the programme for user-driven Research based Innovation (BIA) to support investigator-sponsored clinical trials Financial Summary (NOK million) Q2 2017 Q2 2016 YTD2017 YTD2016 FY 2016 Operating revenues  -    -    -    -    -  Operating expenses  33,8  66,5  99,6  87,2  131,6Operating profit (loss)  -33,8  -66,5  -99,6  -87,2  -131,6Profit (loss) after tax  -34,1  -66,2  -99,1  -86,5  -129,8 Basic and diluted  -0,70  -225,83  -2,41  -307,27  -419,68earnings (loss) pershare (NOK)Cash position end of  440,3  105,2  440,3  105,2  161,8period Presentation and Webcast Details A presentation by BerGenBio’s senior management team will take place at 10:00 am CEST at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Tjuvholmen The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished. The results report and the presentation will be available at www.bergenbio.com in the section: Investors/Reports and presentations from 7:00 am CET the same day. -Ends- About BerGenBio ASA BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of Axl kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers. BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated in the second half of 2018. It is the only selective Axl inhibitor in clinical development. The Company sponsored clinical trials are: · BGB324 as a single agent and combination therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS) · BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC) · BGB324 with KEYTRUDA® (pembrolizumab) in advanced adenocarcinoma of the lung, and · BGB324 with KEYTRUDA in triple negative breast cancer (TNBC). The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co. Inc. (MSD), through a subsidiary. In addition, a number of investigator-sponsored trials are underway, including a trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining BGB324 with docetaxel in advanced NSCLC. BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with BGB324. This will facilitate more efficient registration trials and support a precision medicine based commercialisation strategy. The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody. For further information, please visit: www.bergenbio.com  KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc.  Contacts  Richard Godfrey CEO, BerGenBio ASA media@bergenbio.com +47 917 86 304 Media Relations David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

BioGaia AB Interim report 1 January – 30 June 2017

Comments from the Managing Director:“Sales in the second quarter of 2017 reached SEK 156 million, which is an increase of 15% compared to the same period of last year. The strong second quarter, when sales to our important market Brazil gained new momentum, meant that for the first six months we achieved sales of SEK 297 million, a gross margin of 75% and an operating profit of SEK 115 million. We are on the right track and continue with the implementation of our strategic initiatives. I am also very pleased that in the quarter we established the subsidiary BioGaia Pharma AB to take advantage of the opportunities to develop drugs identified in the R&D activities conducted as part of our core business,” says Axel Sjöblad, Managing Director of BioGaia AB.  Second quarter 2017(The figures in brackets and comparative figures in the text refer to the same period of last year. The comparative figures in the balance sheet refer to 31 December 2016.) · Net sales amounted to SEK 156.0 million (136.0), an increase of 15% (excluding foreign exchange effects, 10%).  · Net sales in the Pediatrics segment reached SEK 132.1 million (106.7), an increase of 24%. · Net sales in the Adult Health segment amounted to SEK 23.0 million (25.7), a decrease of 11%. · Operating profit was SEK 59.7 million (53.4), an increase of 12%.  · Profit after tax was SEK 47.2 million (38.6), an increase of 22%.  · Earnings per share totalled SEK 2.72 (2.22). No dilutive effects arose during the period. · The period’s cash flow was SEK -117.3 million (-75.0).  Key events in the second quarter of 2017 · BioGaia’s oral health probiotic to be launched in three new markets. · BioGaia sets up subsidiary for the development of probiotic drugs. 1 January – 30 June 2017  · Net sales amounted to SEK 297.2 million (269.9), an increase of 10% (excluding foreign exchange effects, 6%).  · Net sales in the Pediatrics segment reached SEK 242.8 million (214.8), an increase of 13%. · Net sales in the Adult Health segment amounted to SEK 49.5 million (46.8), an increase of 6%. · Operating profit was SEK 115.5 million (104.7) ¹, an increase of 10%.  · Profit after tax was SEK 90.1 million (77.3) ¹, an increase of 17%.  · Earnings per share totalled SEK 5.20 (4.46) ¹. No dilutive effects arose during the period. · The period’s cash flow was SEK -39.8 million (-35.4) ¹. Cash and cash equivalents at 30 June 2017 amounted to SEK 202.6 million (243.1).  1) Excluding the former subsidiary Infant Bacterial Therapeutics (IBT) AB, which was distributed to the shareholders in March 2016.Teleconference: Investors, analysts and the media are invited to a teleconference 18 August 2017, at 9:30 a.m. CET. The presentation will be held by Managing Director Axel Sjöblad. To participate in the teleconference, please see telephone numbers at www.biogaia.com/investors/agenda/. The teleconference can also be followed at https://tv.streamfabriken.com/biogaia-q2-2017.This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 18 August 2017 kl 8:00 a.m. CET. 

Immunovia invites to a conference call on August 23, 2017

The conference call, scheduled to last for a maximum of one hour, will be held in English. Following a presentation of the company by CEO Mats Grahn, we offer the opportunity to ask questions. Please call a few minutes before the conference call begins. Date: August 23, 2017Time: 16:00 (CET) Phone numbers:SE: +46 8 56642690CH: +41 225675548DE: +49 69222229046DK: +45 35445575UK: +44 2030089808US: +1 855 8315945 On Immunovia's website under Investors/Financial Reports there will be an MP3 file for those who want to listen to the conference call later, the file is available within two hours of the end of the conference call. The half-year result is expected to be published at 8:30 AM (CET) on August 23. For questions as well as for appointment of interviews:ir@immunovia.com  About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)  Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com. ###

Profitable growth and high level of ordersreceived

April – June 2017 ·  Operative net sales SEK 12,813 million (12,781) ·  Operative operating profit SEK 631 million (624) ·  Operative operating margin 4.9 percent (4.9) ·  Pre-tax profit SEK 623 million (609) ·  Earnings per share SEK 1.80 (1.74) ·  Orders received SEK 12,156 million (10,165) ·  Cash flow before financing SEK -1,105 million (6) January – June 2017 ·  Operative net sales SEK 23,909 million (21,473) ·  Operative operating profit SEK 947 million (812) ·  Operative operating margin 4.0 percent (3.8) ·  Pre-tax profit SEK 934 million (755) ·  Earnings per share SEK 2.74 (2.16) ·  Orders received SEK 23,270 million (22,051) ·  Order backlog SEK 37,313 million (33,457) ·  Cash flow before financing SEK 683 million (916) ·  Net debt SEK 2,707 million (3,154) ·  Equity/assets ratio 29.3 percent (27.5)   “Peab’s order situation has been consistently growing for some time which has contributed to higher net sales and a better result for the first half-year 2017. This high level of orders together with select investments in Project Development and Industry create stable conditions for the future”, says Peab’s CEO Jesper Göransson. This information is information that Peab AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at August 18, 2017, 08:00 a.m. CET.For further information, please contact: Jesper Göransson, CEO +46 431 89338 Charlotte Hagö, CIO +46 725 334545

Medivir licenses exclusive rights to MIV-802 for Greater China to Ascletis

Stockholm, Sweden and Hangzhou, China— Medivir AB (Nasdaq Stockholm: MVIR) and Ascletis today announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China.Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered royalties on net sales of MIV-802 containing products. Ascletis will fund clinical development, manufacturing and commercialization of MIV-802 in Greater China.“We are pleased to have Ascletis as a partner with their track record in advancing development of pharmaceuticals in Greater China and their portfolio of antivirals with which to create a combination drug against hepatitis C” said Christine Lind, CEO of Medivir.“Ascletis has filed an NDA in China for its first HCV NS3/4A medicine, danoprevir, at the end of 2016 and has an HCV NS5A inhibitor in the late stage clinical development. By acquiring MIV-802, a nucleotide NS5B inhibitor, Asceltis is committed to treating, eventually eliminating, hepatitis C in greater China with its multiple leading antiviral combinations including MIV-802,” said Dr. Jinzi J. Wu, CEO of Ascletis.For further information, please contact:Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580Jianjiong Wang, Associate Director, Corporate Affairs, mobile: +86 181 0650 1929. Email: pr@ascletis.comAbout MIV-802MIV-802 is a potent, pangenotypic nucleotide inhibitor of the HCV NS5B polymerase. Hepatitis C treatments comprise combinations of pharmaceuticals with different antiviral mechanisms. Preclinical data indicate that MIV-802 can be used effectively in combination with other classes of antiviral agents for the treatment of HCV, including protease inhibitors, non-nucleoside NS5B inhibitors, and NS5A inhibitors.About MedivirMedivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.About AscletisAscletis is a leading biotechnology company dedicated to discovering, developing and commercializing new treatments for liver diseases. Ascletis has assembled an entrepreneurial management and senior scientific team with a track record of successful pharmaceutical discovery and development at major global pharmaceutical companies. To date the company has added four late-stage candidates to its product portfolio: Danoprevir (ASC08), an NDA-filed HCV protease inhibitor, licensed from Roche; Ravidasvir (ASC16), phase II completed HCV NS5A inhibitor, licensed from Presidio Pharmaceuticals; ASC06, a clinical stage, first-in-class, RNAi therapeutic for the treatment of liver cancers, licensed from Alnylam Pharmaceuticals; and ASC09, a phase IIa completed HIV protease inhibitor, licensed from Janssen, a Johnson & Johnson company.For more information, please visit www.ascletis.com or www.ascletis.com.cn

Isofols appoints Sven Erickson as Chief Commercial Officer

Isofol Medical AB (publ), a clinical stage oncology company about to enter a registration study within first line colorectal cancer treatment, announces the appointment of Sven Erickson as Chief Commercial Officer. He will lead the licensing and commercialization efforts of the company’s lead candidate Modufolin®. Mr. Erickson is a life Science executive with over 20 years’ experience from research, clinical development and successful commercialization of diagnostics and pharmaceuticals, especially in the oncology field. With a strong track record of negotiating international license deals, Mr. Eriksson will be an important driving force behind the commercialization of Modufolin® and the company’s partnering efforts in preparations of a potential market approval. Anders Rabbe, CEO of Isofol, says "Sven’s appointment is in line with Isofol’s strategy to bolstering our commercial and partnering capabilities as the pivotal study of Modufolin® draws closer. His consistent, successful track record and strong business expertise will ensure that Modufolin® reaches a favorable licensing agreement and strong presence at future partnering and scientific conferences. It’s with great pleasure I can welcome Sven to Isofol during these exciting times "   Prior to joining Isofol, Mr. Erickson served as Director of Medical Affairs in the Nordic region at PTC Therapeutics. Preceding his employment at PTC Therapeutics was his role as Product Search and Evaluation Manager at Medivir, a research-based pharmaceutical company with focus on oncology, managing in-licensing operations. Before joining Medivir in 2014, Mr. Erickson also held different positions at Novartis including Scandinavian Medical Head Critical Care. Mr. Eriksson is a PhD in Experimental Oncology from The Karolinska Institute, Sweden.  "I’m more than excited to join Isofol and its great team," said Dr. Erickson, "and I am looking forward to put Modufolin® at the top of the mind of potential collaborators and, ensure in time, the commercialization of Modufolin®." For more information, please contact: Anders Rabbe, CEO, Isofol Medical AB E­mail: anders.rabbe@isofolmedical.com Phone: +46 (0)707 646 500 About Modufolin® Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study. About Isofol Medical AB Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB. www.isofol.se

Continued focus and consolidation

Second quarter: April-June 2017 · Operating revenue amounted to SEK 1,678 M (1,534), an increase of 9% or SEK 144 M. · Operating profit was SEK 74 M (56) including SEK 15 M in capital gain from sale of real estate.   · Net profit after tax for the period was SEK 48 M (34). · Earnings per share for the period before and after dilution were SEK 0.91 (0.64). · Operating cash flow was SEK 45 M (29).   · A dividend for the 2016 financial year of SEK 0.50 per share was approved at the 2017 Annual General Meeting, corresponding to approximately SEK 27 M. Interim period January-June 2017 · Operating revenue amounted to SEK 3,326 M (3,005), an increase of 11% or SEK 321 M. · Operating profit was SEK 140 M (98) including SEK 15 M in capital gain from sale of real estate. · Net profit after tax for the period was SEK 89 M (18). · Earnings per share for the period before and after dilution were SEK 1.67 SEK (-0.08). · Operating cash flow was SEK 28 M (58).  Events during the second quarter · To focus and concentrate Elderly Care operations on elderly housing under our own management and to further strengthen opportunities for continued profitable growth, Humana decided during the quarter to dispose of its home care service operations. A sale agreement has been signed with Attendo. The annual divested revenue amounts to approximately SEK 250 M. Approval from the Swedish Competition Authority was received on 20 July 2017 and the sale is expected to be completed in the third quarter of 2017. · Humana has sold 16 properties in Sweden to Hemfosa Fastigheter. The purchase price, which will be through a sale-and-leaseback transaction, amounts to SEK 135 M and the capital gain amounts to SEK 15 M.    Events after the end of the period · Humana signed an agreement to establish an elderly housing unit under own management in Kungsängen. The unit, which is scheduled to open in 2019, has 72 flats and is Humana’s fifth elderly housing unit under own management. · Humana has acquired Nordic Senior Services Oy in Finland.   Conference callA conference call will be held today, 18 August, at 09:00 CET, at which President and CEO Rasmus Nerman and CFO Ulf Bonnevier will present the report and answer questions. To participate, please call: SE: +46 8 566 426 63UK: +44 203 008 98 13USA: +1 855 831 59 45 For more information, please contact:Ulf Bonnevier, CFO, +46 (0)70-164 73 17, ulf.bonnevier@humana.seCecilia Lannebo, Head of Investor Relations, +46 (0)72-220 82 77, cecilia.lannebo@humana.se

Nexam Chemical Holding AB (publ) Interim Financial Report 1 January – 30 June 2017

Second quarter at a glance Operational: · The highest sales ever in the company´s history for a single quarter.   · Delivery completed to additional production facility at existing pipe customer at the same time as access to specific polyethylene is holding back volume growth. Alternative suppliers are under evaluation. · Funding from Vinnova granted for development of graphene-modified composites for long-term and high temperature applications together with SWEREA Sicomp. · Nexam Chemical approved for listing on Nasdaq First North Premier. Financials: · Net sales for the second quarter totaled SEK 4,577,000 (4,242,000). · The operating loss for the second quarter SEK -5,791,000 (-5,728,000). · In comparison to the beginning of the year, cash and cash equivalents amounted to SEK 118,983,000 (133,147,000). · Cash flow from operating activities was SEK -4,762,000 (-6,783,000). Lund 18 August, 2017 The Board of Directors These financial statements have not been reviewed by the Company´s auditor. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com  This information is information that Nexam Chemical Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on August 18, 2017. ___________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com . The company´s Certified Adviser is FNCA Sweden AB.

Interim Report (January - June 2017)

January - June 2017Net sales amounted to SEK 903.8 million (847.4), a revenue growth of 6.7 percent. Adjusted for acquisitions and FX, the organic revenue growth amounted to 1.1 percent.Operating profit before depreciation and amortization (EBITDA) amounted to SEK 162.2 million (177.5), corresponding to an EBITDA margin of 17.9 percent (20.9), and 8.6 percent lower EBITDA compared to the corresponding period previous year.Net financial income/expense includes net foreign exchange differences of SEK -8.8 million (9.9).Profit for the period amounted to SEK 36.6 million (52.6).Earnings per share after dilution amounted to SEK 0.13 (0.18).Cash flow from operating activities amounted to SEK 83.0 million (103.8). April – June 2017Net sales amounted to SEK 475.2 million (452.3), a revenue growth of 5.1 percent. Adjusted for acquisitions and FX, the organic revenue was -1.7 percent lower than the corresponding period previous year.Operating profit before depreciation and amortization (EBITDA) amounted to SEK 90.4 million (116.1), corresponding to an EBITDA margin of 19.0 percent (25.7) and 22.1 percent lower EBITDA compared to the corresponding period previous year.Net financial income/expense includes net foreign exchange differences of SEK -7.8 million (17.9).Profit for the period amounted to SEK 28.3 million (50.5).Earnings per share after dilution amounted to SEK 0.10 (0.17).Cash flow from operating activities amounted to SEK 31.9 million (94.8). Notable events during the second quarterNashville, Tennessee signed new contract with Opus Inspection.Opus Inspection acquired European RSLab.Opus received notice of award from Government of Sindh, Pakistan.Ohio signs renewed contract with Opus Inspection.Opus acquired U.K. based Autologic Diagnostics.Opus entities named in lawsuit.Opus issued Taxable Corporate Notes in the U.S. amounting to USD 25 million. Gothenburg in August 2017Opus Group AB (publ)

INTERIM REPORT 1 APRIL – 30 JUNE, 2017

Second quarter 2017, compared to 2016, Group » Group net sales increased by 33% to SEK 622,897 (469,380) » Other operating income including capitalized development expenditure amounted to SEK 607,140 (381,298) » Loss before tax amounted to SEK –12,990,707 (–16,473,988) » Earnings per share (weighted average) amounted to SEK –0.45 (–1.03) Significant events during the second quarter   » Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant was performed » Episurf Medical obtained further granted patents in Australia, US and Europe » Episurf Medical strengthened the company’s management group » Episurf Medical reached milestone of 200 implants » Episurf Medical continued its communication with the US Food and Drug Administration (FDA) » Episurf Medical’s Board named Pål Ryfors new CEO and appointed Veronica Wallin as new CFO » Episurf Medical appointed Dr Michael Manley Special Advisor for the US strategy Significant events after the second quarter » Dennis D. Stripe re-assumed the position as non-executive chairman of the board » Case-report with clinical data of Episealer® patient was published » Another preclinical paper on the Episealer® Implant published » Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independ­ent hospital providers » Episurf Medical reported a brief clinical update » Management group changes in Episurf Medical were announced » Episurf Medical reached milestone of 250 implants For more information, please contact: Pål Ryfors, CEO, Episurf Medical  Tel: +46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 18 August 2017.

Medivir initiates clinical study of birinapant in combination with KEYTRUDA® (pembrolizumab) in patients with treatment-refractory solid tumours

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in the company’s phase I/II study of birinapant in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab), which is marketed by MSD (known as Merck & Co., Inc, Kenilworth, NJ, USA in the US and Canada). The objectives of the study are to evaluate the safety, tolerability and preliminary efficacy of this combination in patients with treatment-resistant solid tumours.About the studyThe multicentre, single arm, open label study, which is primarily being run in the US, will be conducted in two parts. In the initial dose escalation (phase I) part of the study, the objective is to identify the recommended phase II dose of birinapant for use in combination with KEYTRUDA®. This is to be achieved by administering increasing doses of birinapant in combination with the approved dose of KEYTRUDA® to cohorts of up to 6 patients with refractory solid tumours.Once the recommended phase II dose has been identified, the second part of the study will begin. The primary objective of the phase II part is to evaluate the safety and tolerability of birinapant in combination with KEYTRUDA® in several cohorts. Each cohort will be made up of patients with the same treatment refractory tumour type. An important secondary objective in the phase II part is the preliminary evaluation of the efficacy of the combination in each of the cohorts.Under the terms of the agreement between Medivir and MSD (through a subsidiary), MSD will provide KEYTRUDA® for this study at no cost to Medivir. Medivir retains full rights to birinapant. Additional details were not disclosed.“The approval of immune check-point inhibitors constituted a remarkable leap forward for many cancer patients, but there still remains a substantial opportunity to improve outcomes. Recent preclinical data have provided a strong scientific rationale for combining birinapant with immune checkpoint inhibitors such as KEYTRUDA®. We are therefore very pleased to enrol the first patient in this combination study, which will allow us to determine its safety and tolerability, as well as its potential efficacy, in patients with solid tumours who have no further treatment options,” said John Öhd, Chief Medical Officer at Medivir.About birinapantBirinapant is a parenterally administered bivalent peptidomimetic of the SMAC protein (Second Mitochondria-derived Activator of Caspases) and is therefore known as a SMAC mimetic compound. Birinapant binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), which both enables apoptosis (programmed cell death) in tumour cells, and activates the immune system, enhancing its attack on the tumour. Birinapant has the potential, through its actions on tumour cells and cells of the immune system, to improve the treatment of several types of cancer when used in combination with other drugs including checkpoint inhibitors and DNA damaging agents.For further information, please contact:Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580John Öhd, CMO Medivir AB, mobile +46 (0) 725 296 200Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 18 August 2017.About MedivirMedivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet the unmet medical needs of cancer patients. Medivir is listed on the Nasdaq Stockholm Mid Cap List.KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Lemminkäinen Corporation announces positive results of Noteholders’ Meeting for its EUR 100,000,000 senior unsecured notes

LEMMINKÄINEN CORPORATION  STOCK EXCHANGE RELEASE 18 AUGUST 2017 AT 11:00 A.M. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. LEMMINKÄINEN CORPORATION ANNOUNCES POSITIVE RESULTS OF NOTEHOLDERS’ MEETING FOR ITS EUR 100,000,000 SENIOR UNSECURED NOTES The meeting of the holders of Lemminkäinen Corporation's (“Lemminkäinen”) EUR 100,000,000 senior unsecured notes due 2019 (ISIN FI4000100508) (the "Notes") was held on August 18, 2017 (the “Noteholders’ Meeting”). The holders of the Notes resolved to approve the proposal relating to granting consents and waivers (the “Consents and Waivers”) and took decisions to amend the terms and conditions of the Notes (the “Amendments”). The Consents and Waivers became effective immediately upon approval at the Noteholders’ Meeting, and the Amendments will become effective at the completion of the statutory absorption merger (the “Effective Date”) of Lemminkäinen into YIT Corporation as announced on 19 June 2017. The payment of the instruction fees in connection with the consent solicitation will occur no later than five (5) business days following the occurrence of the Effective Date. The details of the terms and conditions of the consent solicitation are set out in the consent solicitation memorandum dated 3 August 2017. Solicitation Agents: Danske Bank A/S: liabilitymanagement@danskebank.dk / +358 10 513 8865 Nordea Bank AB (publ): NordeaLiabilityManagement@Nordea.com / +45 61612996 Tabulation Agent: Intertrust (Sweden) AB: trustee@intertrustgroup.com / +46 73 582 55 65 LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:Ilkka Salonen, CFOTel. +358 20 71 53304ilkka.salonen@lemminkainen.com DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,700 professionals we employ, we build a sustainable society. In 2016, our net sales were EUR 1.7 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

Telecommunications: Composite enablers for future smart cities

The construction market already presents a huge growth opportunity for the composites industry. But while many drivers for the increased use of composites in building – such as high strength, lightweight and design freedom – are well established, an emerging factor which will further favour their adoption is connectivity. As increasing urbanization and digitalization place more and more demands on telecommunications networks the use of RF transparent materials will become key. Rapid urbanization is a global megatrend shaping the future of our world. Already, more than half of the world's population lives in urban areas, and this is expected to rise to 70% by 2025, with the majority of this growth taking place in Africa and Asia.   This accelerating urbanization will lead to the creation of more 'megacities' of 10 million and more inhabitants. By 2030, there are expected to be at least 40 such megacities, with seven out of the top ten being in Asia. These urban areas will be the powerhouses of the global economy, exerting an economic strength greater than that of many countries.   As powerful economic hubs and centres for innovation and productivity, cities will continue to attract millions of people seeking greater opportunities, more prosperity and a better quality of life. Managing this growth in a sustainable way will create huge challenges and require immense investments in infrastructure and services. Close to $78 trillion is expected to be spent on infrastructure worldwide between 2014 and 2025, according to PricewaterhouseCoopers.  The future is smart One focus for future investment is telecommunications. Future cities will be smarter, implementing digital and data-driven solutions to help them operate more efficiently and provide new services for residents and businesses. This will only be possible with an effective and reliable telecommunications network. By 2035, analysts predict that in addition to computers and smartphones there could be 1 trillion connected devices worldwide (the envisaged Internet of Things) and current networks will be insufficient. A new digital infrastructure and fast, high capacity networks will be essential to meet ever growing needs for data transmission.   The 5th generation mobile networks, 5G, scheduled for roll out from 2020 onwards, are the proposed answer. Operating at higher frequencies than the current 4G/LTE standard, 5G will offer faster data transmission of 20 GB/s and support at least 1 million connected devices per square kilometer. With a reduced latency of less than 1 ms, 5G will also guarantee the safety of autonomous vehicles. On the downside, the higher frequency (3.5-78 GHz) 5G signals will have shorter (millimeter) wavelengths and will not travel as far as the previous longer wave signals. A dense network of antennas will be needed to boost the 5G signal locally. Integrating these thousands of unsightly antennas into city infrastructure, and preferably hidden from view, will be a challenge. A second issue relates to signal attenuation within buildings. All RF signals lose strength as they travel through intervening materials (to an extent determined by the material), but shorter wavelength signals are attenuated more rapidly than those with longer wavelengths. The trend towards better insulated, more energy efficient buildings is already exacerbating this problem and it will become even more of an issue with the move to 5G. With these factors coming into play, when selecting materials for the next generation of city infrastructure architects and planners must now also take into account 5G signal penetration. And this is where RF transparent composites can earn an expanded role. Composites and city infrastructure  High strength and stiffness, low weight, corrosion resistance, low maintenance requirements, thermal stability and design freedom are some of the properties which make composites attractive construction materials for future cities. Composites are already extensively used in the manufacture of energy efficient windows and doors, facades and cladding, bridges and bridge reinforcements, street lighting and furniture, and rail and metro applications such as platforms and access structures. Composites also enable modular building concepts for the creation of affordable housing. In addition, glass fiber composites possess good dielectric properties and have been used in telecommunications applications such as base stations and radomes for many years, where they offer minimal signal attenuation. Exel Composites has a long history of supporting the telecommunications industry with innovative composite solutions. We also have extensive experience in developing composite structures for demanding applications in the building and construction market. Recognising the challenges facing these sectors in the future urban environment, and aware of the possibilities that composites offer to both, Exel is participating in a groundbreaking initiative aimed at developing 5G-enabled city infrastructure. Smart light pole network LuxTurrim5G is a joint R&D project focused on Smart City Digital Ecosystem Creation, bringing together 10 innovative companies and three respected research institutes. The project partners, including Nokia Bell Labs, Teleste, Vaisala, Tekes, Premix, Lammin Windows and Doors, C2 SmartLight, Tampere University of Technology (TUT) and VTT, offer a breadth of expertise spanning RF technologies, materials, urban planning and construction, and innovation management. The ambitious three-year €15 million programme aims to develop enablers for the future smart city, making big data capacity available for residents and businesses through a network of 'smart light poles.' As well as providing energy-efficient lighting, the composite poles with integrated miniturized antennas and base stations will create a high-capacity 5G data transmission network. Sensors, information displays, cameras and other devices will also be incorporated in order to trial a variety of novel services and business concepts. Composite light poles are a clever way to disguise the thousands of antennas which will be needed for the 5G network. As a leading manufacturer of composite antenna radomes and structures for GSM, 3G and 4G base stations, and utilising many years of experience in designing and manufacturing poles for airport approach lighting systems and other specialized applications, Exel has proposed a concept for the light pole based on a three pultruded sections. The project will also construct test houses using different materials to compare the signal penetration through composites compared with conventional building materials and structures. One building element designed to serve as a wall structure has already been manufactured. This is based on a sandwich panel comprising a PIR foam core with composite skins and incorporates composite I beams and window frames. The excellent thermal insulation properties of glass fiber composite means this type of building element meets the requirements of energy efficient (lower lambda) buildings, while also allowing RF signal penetration. A pilot project is currently underway in the Finnish city of Espoo, where Nokia is providing a 5G test bed network for use by the consortium partners. Materials testing will start in August. Different composite materials and constructions will be studied to determine the best combinations for optimal signal penetration.   A huge opportunity The increasing importance of RF transparent materials for next generation city infrastructure opens up a new market opportunity for the composites industry far beyond the scale of current construction applications. While the total market for composites in the global construction industry was valued at €11.3 billion in 2016, the market for 5G built infrastructure is expected to be worth €160 billion by 2025.   To seize this opportunity all players in the composites supply chain need to be involved. Smart lighting pole networks will provide lucrative business opportunities for companies both large and small in the future, while energy efficient building systems with improved RF signal penetration present further opportunities for innovative designers, manufacturers and suppliers.  Through the LuxTurrim5 project and close collaboration with leading mobile network operators Exel Composites will continue to pursue next generation telecommunications solutions. With our unrivalled composites design expertise and high volume manufacturing capabilities, we are ready to partner with organisations seeking to take on the challenges and opportunities presented by the smart cities of the future. For further information on Exel Composites' innovative telecommunications solutions, please contact Mikko Lassila (mikko.lassila@exelcomposites.com), Product Business Owner, Telecommunication.

Moberg Pharma divests Fiber Choice for $6.7 million

Fiber Choice® is a well-established digestive health brand, with products for daily fiber supplementation. Moberg Pharma acquired Fiber Choice® together with PediaCare®, New Skin® and Dermoplast®, in 2016 from Prestige Brands, Inc. As communicated previously, the primary purpose of the acquisition was to add New Skin® and Dermoplast®, two strategic assets in specialty skin care, to the Moberg Pharma portfolio. Divesting the brand enables Moberg Pharma to focus resources on its strategic brands. This transaction follows the December 2016 divestment of PediaCare® and results in a capital gain of circa $1.6 million. During the period of ownership (July 7, 2016 – June 30, 2017) Fiber Choice® contributed net sales of $7.1 million, however this figure also includes discontinued product items.    The transaction is expected to close within the next four weeks. “We are pleased with the agreement with Caret Pharma LLC. which enables us to increase focus on the core Moberg Pharma portfolio. We have now successfully divested both non-core brands included in the acquisition from Prestige Brands, while the acquired strategic brands are developing well”, says Peter Wolpert, CEO Moberg Pharma. About this informationThis information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. CET on August 21th 2017.

Elisabeth Peregi appointed interim CEO of Lindex

STOCKMANN plc, Changes board/management/auditors 21.8.2017 at 9:45 EET Ingvar Larsson, CEO of Lindex, has decided to resign from his post. Elisabeth Peregi, currently the Country Manager of Lindex Sweden, has been appointed the interim CEO of Lindex with immediate effect. Elisabeth Peregi (born 1971), M.Sc. (Econ.), has held several management positions at Lindex. She worked as the Lindex CFO from 2010 to 2013 and, before that, as Head of Franchise Business and Country Manager for Norway. Elisabeth will report to Stockmann’s CEO, Lauri Veijalainen, who will start as the Chairman of the Lindex Board of Directors. The previous chairman, Per Sjödell, continues as a member of the Stockmann Board. Ingvar will now leave his position as the CEO, but he will be available for the company during his period of notice. “I would like to thank Ingvar for his excellent work in leading the company and strengthening the Lindex position as one of the leading European fashion chains. I am confident that the company will continue to be in good hands with Elisabeth who has long experience in demanding sales positions at Lindex, a strong financial background and the drive to lead the company forward,” says Lauri Veijalainen, CEO of Stockmann. Further information:Lauri Veijalainen, CEO, tel. +358 9 121 5062Nora Malin, Director, Corporate Communications, tel. +358 9 121 3558 www.stockmanngroup.com  STOCKMANN plcLauri VeijalainenCEO Distribution:Nasdaq HelsinkiPrincipal media

TMG LAUNCHES NEW COLLABORATIVE SOFTWARE PLATFORM, TEMBA

London – 21 August 2017 - The Marketing Group plc (TMG) today announced the launch of Temba, its inter-agency collaboration platform, to facilitate greater teamwork across the network. Temba will work to leverage the full potential of the group, uniting all agencies across TMG to create teams for global briefs. It is a crucial step towards TMG becoming an effective, agile, marketing platform. Temba allows teams from around the world to identify skills, experience, sectors and specialisms across the group, including regional breakdowns, to facilitate cross-agency co-creation for international clients. Temba also features an adaptive mobile interface and an AI powered bot that connects to Slack – a tool that all the agencies around the world already use to communicate in real time. Named after Temba Tsheri, the youngest Sherpa to reach the summit of Mount Everest, the platform embodies the independent spirit of TMG and is borne out of the network’s strategy to provide brands an agile solution to global briefs. TMG CEO, Adam Graham said: “Temba is a critical tool for us in further leveraging the immense talent and capability that we hold as a network. It’s designed by the group for the group, which is a great way of ensuring it includes all sectors the TMG network needs. We’re also immensely proud that we will be launching the platform ahead of some of the world’s largest marketing networks, showing, if proof were needed, that an agile approach is most often the way to deliver the best results, fast.” The vision for the Temba platform was conceived during TMG’s New York founders summit in Spring 2017 and was designed and built through a global collaboration between Nice & Polite, Channel Zero and Marker Studio – three TMG agencies in three different countries. -ENDS- For more information, please contact Adam Graham, CEO Email: investorrelations@tmg-plc.com Media Jaime Carron Phone: 0207 1481606 Email: jaime.carron@tmg-plc.com The Marketing Group plc (“TMG”) in brief    TMG is building a global full-service marketing network that respects the individual cultures of each agency that joins. By providing a supportive platform for growth, and an agile management approach, TMG aims to provide a fresh alternative to the big holding companies: Independent Spirit - Global scale. Each company within the group provides specialist marketing services brought together, within complementary communities of practice, to form an international network that can address a global market. The central team supports its subsidiaries through a lean and nimble structure that can respond quickly to change and provide highly effective solutions for clients. The Marketing Group is listed on Nasdaq First North, Stockholm. www.tmg-plc.com. Mangold Fondkommission AB, +46 8-5030 15 50, is the company’s Certified Adviser and liquidity provider.

Scania hits the construction zone

“Scania has millions of followers among customers, drivers and fans online and naturally we have invited all of them to join us for this momentous event,” says Erik Ljungberg, Senior Vice President, Corporate Relations. Over the coming countdown days, Scania will provide advance peeks of this new marvel on the web and social media. “We know that many are eager to see what Scania holds in store and although we will save the best for last, we can promise some exciting insights.” With the new dedicated construction range, Scania challenges the market for the most durable trucks for the toughest applications. Years of development have been invested to design the range for the many applications in the many-faceted construction industry. All will be revealed on 4 September. Viewers will see and hear all about the features of these trucks. During the live webcast from an actual construction site, the new range will be put to the test and viewers will have the opportunity to see for themselves how the trucks perform under tough conditions. The construction range represents the second stage in Scania’s new generation trucks. Following the release of the universally acclaimed long-haulage trucks last year, Scania builds on the technological innovations to take on yet another transport challenge. Join us as we unveil this exceptional truck range. Share the moment online via the live webcast or on Facebook Live. Sign up for an event reminder at nextgenscania.com to make sure you don’t miss this event. For further information, please contact: Örjan Åslund, Head of Product Affairs, Scania Trucks Tel: + 46 70 289 83 78, Email: orjan.aslund@scania.com

BAKKAFROST: Operational EBIT of DKK 459 Million for the Second Quarter of 2017

The total volumes harvested in Q2 2017 were 18.4 thousand tonnes gutted weight. Bakkafrost trans­ferred 1.9 million smolts in Q2 2017. In Q2 2017, Havsbrún sourced 163.1 thousand tonnes of raw material. The farming segment made an operational EBIT of DKK 489.5 million for Q2 2017, which corresponds to NOK 33.50 per kg. The VAP segment made an operational EBIT of DKK -54.5 million for Q2 2017. The salmon spot prices have been on record high levels since 2016 and this continued in Q2 2017. The high salmon spot price is positive for the farming segment. As in previous quarters, when the salmon spot prices are high, the VAP segment had negative margins in Q2 2017. The combined farming and VAP segments made an operational EBIT of DKK 435.0 million for Q2 2017, which corresponds to NOK 29.77 per kg. The FOF segment (fishmeal, oil and feed) made an operational EBITDA of DKK 47.8 million for Q2 2017. Commenting on the result, CEO Regin Jacobsen said: “Bakkafrost’s three segments had all a very high activity level in the second quarter of 2017. Havsbrún received a record high volume of 163.1 thousand tonnes of raw material. The Farming segment har­vested a record high volume of 18.4 thousand tonnes gutted weight, and the VAP segment produced 5.3 thousand tonnes gutted weight. Bakkafrost focuses on raising a sustainable premium quality salm­on with emphasis on animal welfare and on preserving the environment. In May 2017, farming site A-71 Funningsfjørður was ASC certified, and Bakkafrost aims to have all its farming sites ASC certified in 2020.” In accordance with Bakkafrost’s dividend policy and the resolution of the Annual General Meeting 2017, Bakkafrost paid out DKK 8.70 (NOK 10.69) per share in April 2017. The total dividend payment was DKK 425.1 million (NOK 522.5 million). In Q2 2017, Bakkafrost’s full-time employees from 2016, still employed at Bakkafrost, have received bonus shares with a total value of 2% of their salary in 2016. In total, Bakkafrost has allocated 19,631 shares to its employees. The total allocation amounted to 4.7 million and was based on the closing share price on the allocation day, 29 May 2017. The Bakkafrost Group’s net interest bearing debt amounted to DKK 559.7 million at the end of Q2 2017. Bakkafrost had undrawn credit facilities of DKK 718.5 million at the end of Q2 2017 and the equity ratio was 64% at 30 June 2017. OUTLOOK Market For the last year or so, the salmon market has been affected by a decline in supply. The main factors behind this are the harmful algal bloom in Chile in February 2016 and the biological issues in Norway. The negative effect of the Chilean algal bloom on supply of salmon continued into H1 2017. Expecta­tions are that global supply of Atlantic salmon will rebound from decline in H1 2017 to an increase of around 8-10% in H2 2017. The latest update from Kontali Analyse estimates the global supply of Atlan­tic salmon to increase around 2% in 2017, compared to -6% in 2016. The market place is one of Bakkafrost’s most significant risk areas. To diversify the geographical market risk, Bakkafrost sells its products to all the largest salmon markets in the world, USA, the Far East, Europe and Russia. Farming The outlook for the farming segment is good. The estimates for harvesting volumes and smolt releases are dependent on the biological development. The biological situation is Bakkafrost’s most important risk area. The confirmed presence of patho­genic ISA-virus at farming site A-73 in March, draws attention to the importance of a high quality vet­erinary system to reduce the biological risk. Harvest of the fish at farming site A-73 was finished on 12th April 2017, and the site is now in fallow for a period of minimum 6 months. Bakkafrost focuses on biological risk continuously and has made several new investments and procedures to diminish this risk. The investments in producing larger smolts will gradually reduce the time needed in the fjords to farm the salmon. This is expected to reduce biological risk and increase the capacity. The capacity growth from this investment program will appear in harvested volumes gradually until 2021. Bakkafrost expects to harvest 53,500 tonnes gutted weight in 2017. Bakkafrost expects to release 11.5 million smolts in 2017, compared with 11.7 million smolts in 2016 and 11.3 million smolts released in 2015 – smolts released by Faroe Farming before becoming part of the Bakkafrost Group are included. The number of smolts released is a key element of predicting Bakkafrost’s future production. Sea lice is an area, which has demanded much effort and is a part of the biological risk. Bakkafrost focuses on using non-chemical methods in treatments against sea lice. In Q4 2016, Bakkafrost invested in a service vessel, M/S Martin, which uses lukewarm seawater treatment against sea lice. M/S Martin started operation in Q1 2017. In addition to M/S Martin, Bakkafrost invested in another service vessel, M/S Róland, in Q1 2017. M/S Róland is equipped with the same system as M/S Martin and is expected to start operation in September 2017. Furthermore, Bakkafrost will increase the use of lumpfish in farming in 2017. VAP (Value added products) Bakkafrost has signed contracts covering around 58% of the expected harvested volumes for the rest of 2017. This corresponds to an expected contract coverage of around 40% for the full year 2017. VAP contracts are at fixed prices, based on the salmon forward prices at the time they are agreed and the expectations for the salmon spot price for the contract period. The contracts last for 6 to 12 months. The long-term strategy is selling around 40-50% of the harvested volumes of salmon as VAP products at fixed price contracts. Selling the products at fixed prices reduces the financial risk with fluctuating salmon prices. The market price for contracted VAP products follows a more stable pattern instead of short-term fluctuations as in the spot market. The price level on long-term contracts are on a higher level than ever before, there are, however, no indications that this price level should decrease significantly. FOF (Fishmeal, -oil and feed) The outlook for the production of fishmeal and fish oil is dependent on the availability of raw material. The ICES 2017 recommendation for blue whiting is 1,342 thousand tonnes, compared with 776 thou­sand tonnes in 2016. Recommendations for herring and mackerel quotas have increased as well. The production of fishmeal and fish oil will most likely increase due to higher quotas and better availability. The major market for Havsbrún´s fish feed is the local Faroese market including Bakkafrost’s internal use of fish feed. Havsbrún’s sales of fish feed in 2017 are expected to be at 85,000 tonnes. Investments In June 2016, Bakkafrost announced a five-year investment plan from 2016 to 2020. The total invest­ments for the period are DKK 2.2 billion, including maintenance CAPEX. Investments of around DKK 100 million in the two service vessels, M/S Martin and M/S Róland during 2017, are not included in the investment plan. The purpose of the investment plan is to continue to have one of the most cost conscious value chains in the farming industry, to carry out organic growth, increase flexibility and reduce the biological risk to meet the future consumers’ trends and to be more end-customer orientated. Bakkafrost aims at being self-supplied with smolts at a size of 500g each. The benefits are a shorter production time at sea as well as reduced biological risk. To reach this goal, approximately half of Bakkafrost’s total investments from 2016 to 2020 will be in hatcheries. Both the harvest operation and the VAP production in the new harvest/VAP factory at Glyvrar have started operation. The harvest operation started in the summer of 2016, and the VAP production started in Q1 2017. The old harvest factories in Klaksvík and Strendur are closed, as well as the old VAP factories in Fuglafjørður and Glyvrar. There are some extra costs during the start-up period, but the investment is expected to result in operational savings of DKK 70-90 million per year with gradual effect from 2017. Bakkafrost has started upgrading the harvest operation in Vágur, Suðuroy. The upgrading cost is ex­pected to be around DKK 35 million. Bakkafrost plans to increase the value of offcuts from salmon harvested and processed in the new harvest/VAP factory. In 2017, Bakkafrost will invest in a new salmon meal and salmon oil plant, located in Fuglafjørður and operated by Havsbrún. The new salmon meal and salmon oil plant is expected to start operation in late 2017 and is expected to have positive margins in 2018. The FOF segment will also invest in a new feed line, which will increase the capacity of the feed production. Free cash flow from operations, existing financing facilities and partly new financing if advantageous will finance the investments. The dividend policy will be unchanged. Financial Favourable market balances in the world market for salmon products and cost conscious production will likely maintain the financial flexibility going forward. A high equity ratio together with Bakkafrost’s bank and bond financing makes Bakkafrost’s financial situation strong. This enables Bakkafrost to carry out its investment plans to further focus on strengthening the Group, M&A’s, organic growth opportu­nities and fulfil its dividend policy in the future. Please find the Company’s Q2 2017 report and the Q2 presentation enclosed. Contacts: Regin Jacobsen, CEO of P/F Bakkafrost: +298 235001 (mobile) Gunnar Nielsen, CFO of P/F Bakkafrost: +298 235060 (mobile) This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. About Bakkafrost: Bakkafrost is the largest salmon farmer in the Faroe Islands. The Group is fully integrated from feed production to smolt, farming, VAP and sales. The Group has production of fishmeal, fish oil and salmon feed in Fuglafjørður. The Group has primary processing in Glyvrar and Vágur, and secondary pro­cessing (VAP) in Glyvrar. The Group operates sea farming in Norðoyggjar, Eysturoy, Streymoy and Suðuroy. The headquarter is located in Glyvrar, and the company has 820 fulltime employees. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada or Japan.

Smart Eye Interim Report 1 January–30 June 2017

Summary Q2 2017 · Net revenue amounted to TSEK 12,114 (10,486), equivalent to an increase of just over 15%. · The operating result was TSEK –9,306 (–3,867), which is in line with the determined expansion with investments in primarily personnel, marketing and sales activities. · The result after financial items was TSEK –9,435 (–4,240). · Profit per share was negative. · Cash and cash equivalents amounted to TSEK 43,244 as at the end of June. · During the period, the establishment of a sales office in the USA proceeded according to plan, with the recruitment of two sales executives with considerable experience from sale of advanced technical systems. · Smart Eye was awarded a new design win from a European premium vehicle manufacturer after the end of the period. January–June 2017 · Net revenue amounted to TSEK 19,747 (16,077), equivalent to an increase of just over 22% compared to the previous year. · Operating profit amounted to TSEK –18,469 (–7,688). · The result after financial items was TSEK –18,717 (–8,464). · The result after tax per share was negative. Comments from the CEO Q2 2017 shows that Smart Eye is continuing to develop according to plan. Thanks to intensive cooperation with our customers, we achieved a 74% revenue increase for the Applied Solutions business area. After the end of the reporting period, we were awarded our third design win. The automotive industry is making major investments to develop technology to improve active safety. A large number of procurement procedures are being held by strategically important vehicle manufacturers. The companies which win these contracts in these early development phases have good opportunities to continue to develop together with OEM. We consider Smart Eye to be well-positioned to be one of the nominated companies, which in turn indicates stable income flows for the Applied Solutions business area for many years to come. For many years, the automotive industry has worked to increase traffic safety. The initial focus was on developing passive safety, which concerns minimising the consequences of any accidents that occur. Today, there is also focus on increasing active safety by implementing systems to reduce the risk of accidents even occurring. The aim is for traffic accidents to be something we can read about in the history books. This will require autonomous vehicles. Autonomous vehicles are defined at five levels, of which level 1 means that the vehicle alerts the driver of any risks, and level 5 signifies that the vehicle is completely autonomous, with no interaction with the driver being required. Until recently, no vehicles had achieved higher than level 2, but this year the first level-3 vehicles were presented by the automotive industry. This major new step means that in certain specific situations, the driver does not have to steer the car at all. Smart Eye believes that driver monitoring will be a central element of autonomous vehicles up to and including level 3. The result will be cars that can adjust their rhythm and distance to other vehicles, but that are also completely autonomous in certain traffic situations. The system is a major step forward for traffic safety. The work on Smart Eye’s two design wins is running according to plan and we are an attractive collaboration partner, thanks to good access to and knowledge of the latest AI technology. In August, Smart Eye was awarded a third design win from an OEM in the premium segment that Smart Eye previously has not worked with. Together with a leading Tier 1 supplier, we will deliver a Driver Monitoring system for a vehicle model based on the vehicle manufacturer’s next production platform. The model is expected to go into production in 2019. The company and Research Instruments products enable customers to measure, monitor and analyse human behaviour in various interesting situations. Development in the university world, space research and the aviation industry, for example, is positive, and Smart Eye is continuing to consolidate itself as a reliable supplier of eyetracking systems to help customers to understand human behaviour. The high investment rate within Research Instruments is in accordance with the long-term plan. This plan requires us to be there for our customers, in order to give on-site support when needed. This means that we are very happy to welcome our first American employees in Detroit! This information is information which Smart Eye AB (publ) is required to disclose under the EU Market Abuse Regulation. The information has been provided by the contact person below for publication on 22 August 2017 at 08:30 CET. 

Brighter's main patent has been approved by United States Patent and Trademark Office.

The United States Patent and Trademark Office (USPTO) has granted Brighter's main patent in the United States, which includes Actiste and its unique ability to integrate all functions in a patient's activity chain into one and the same device, i.e. measuring and analyzing a biomarker (e.g. blood glucose), and injecting medicine (e.g. insulin). “The approval of our main patent means that an important piece in our global expansion plan is now in place. The potential in the United States is enormous given the large number of people living with diabetes there and across the entire American continent. And although we chose to initially launch the solution in Sweden, Indonesia and Thailand, the US, as well as major parts of Latin America, are important markets that we expect to expand into in the future," says Truls Sjöstedt, Brighter's CEO and founder. The grant concerns Brighter's main patent, which protects the company's unique integration of all functionalities, i.e. measuring and analyzing a biomarker and injecting medicine into one and the same instrument. Actiste is the company's first application based on this, which means a mobile-connected and fully integrated tool for diabetic blood sampling, blood sugar analysis and insulin injection. The US Patent Office's decision implies that the Company has all rights to the patent and its associated patent family. In order to be able to sell Actiste on the US market, an approval of the Federal Drug Administration (FDA) is required. In the development of Actiste, Brighter has taken into account American standards and partly developed its ISO 13485 quality system for the development and production of medical devices to ensure that it also complies with FDA processes and standards. This means that Brighter can apply for FDA approval and/or clearance without further investment in adapting the design of Actiste, in systems and document management. Brighter's patent strategy is based on the main patent and where the company's ongoing research and development, resulting in new patents, complements and strengthens the company's intellectual property protection, which in turn extends the life of existing patents. According to the International Diabetes Federation today, about 10.8 percent of the United States population is suffering from diabetes, which corresponds to approximately 29 million people. This means that the country has the most diabetic in the world, after China and India. In addition to the 29 million people already living with diabetes in the country, it is estimated that there are about 86 million Americans who are in a precursor to the disease, which leads to an increased risk of suffering from diabetes and other chronic diseases. The US market is considered to be the largest and most profitable market for medical devices. For more information, please contact:Truls Sjöstedt, CEO                   Tel: +46 709 73 46 00                   Email: truls.sjostedt@brighter.se  Henrik Norström, COO                   Tel: +46 733 40 30 45                   Email: henrik.norstrom@brighter.se About Brighter AB (publ)       Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on NASDAQOMX First North/BRIG  . Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50,  CorporateFinance@remium.com ,   www.remium.com . This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:30 CET on August 22, 2017.